stella
← For Researchers/Prostate Cancer/Research Sites

Prostate Cancer Research Sites

Sites currently running trials · ranked by activity

EndometriosisLong COVIDALSPTSDSickle Cell DiseaseLupusProstate CancerMenopauseLp(a)

2738 sites · 3561 trials · August 2026

Recruiting
Opening soon
Active · not recruiting
1

Memorial Sloan Kettering Cancer Center

New York · New York · United States

7 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
Open Door for Cancer mental health intervention compared to usual care for older adults with depression and cancer diagnosis.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06037954 ↗
2

Carolina Urologic Research Center

Myrtle Beach · South Carolina · United States

7 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
3

Institut Bergonie

Bordeaux · France

6 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
4

UPMC Hillman Cancer Center

Pittsburgh · Pennsylvania · United States

6 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
5

National Institutes of Health Clinical Center

Bethesda · Maryland · United States

5 trials
IL-15 superagonist N-803 alone or combined with vaccine ETBX-071 is tested in men with prostate cancer recurrence after radiation.
National Cancer Institute (NCI)Ph 2NCT07686380 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
6

Washington University School of Medicine

St Louis · Missouri · United States

5 trials
Fluorthanatrace imaging and blood tests to predict treatment response to PARP inhibitors in metastatic prostate cancer.
Washington University School of MedicinePh 2NCT07723651 ↗
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
7

Yale University

New Haven · Connecticut · United States

5 trials
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
8

UC San Diego Moores Cancer Center

La Jolla · California · United States

5 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
9

Ohio State University Comprehensive Cancer Center

Columbus · Ohio · United States

5 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
10

Colorado Clinical Research

Lakewood · Colorado · United States

4 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
11

Peter MacCallum Cancer Centre

Melbourne · Australia

4 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
12

Liga Norte Riograndense Contra O Cancer

Natal · Brazil

4 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
13

Sunnybrook Health Sciences Center

Toronto · Ontario · Canada

4 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
14

Centre Leon Berard

Lyon · France

4 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
15

Mayo Clinic in Rochester

Rochester · Minnesota · United States

4 trials
Adaptive radiation therapy with two treatments compared to standard stereotactic ablative radiotherapy with five treatments for localized prostate cancer.
Mayo ClinicRecruitingNCT06325046 ↗
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
16

Comprehensive Cancer Centers of Nevada

Las Vegas · Nevada · United States

4 trials
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
17

Medical University of South Carolina

Charleston · South Carolina · United States

4 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2TERMINATEDNCT04585750 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
18

Asan Medical Center

Seoul · South Korea

4 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
19

University of Kansas Hospital-Westwood Cancer Center

Westwood · Kansas · United States

4 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
20

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters · Missouri · United States

4 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
21

Siteman Cancer Center at West County Hospital

Creve Coeur · Missouri · United States

4 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
22

Siteman Cancer Center-South County

St Louis · Missouri · United States

4 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
23

University of California Davis Comprehensive Cancer Center

Sacramento · California · United States

4 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
24

Smilow Cancer Center/Yale-New Haven Hospital

New Haven · Connecticut · United States

4 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
25

Wayne State University/Karmanos Cancer Institute

Detroit · Michigan · United States

4 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
26

Nanjing Drum Tower Hospital

Nanjing · China

3 trials
Abiraterone acetate tablet formulation safety and effectiveness study in Chinese men with metastatic prostate cancer.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07721532 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
27

Columbia University Medical Center

New York · New York · United States

3 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
28

Peking University First Hospital

Beijing · China

3 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
29

The First Affiliated Hospital of Xian Jiaotong University

Xi'an · China

3 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
30

Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie

Koszalin · Poland

3 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
31

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy

Warsaw · Poland

3 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
32

Dana Farber Cancer Institute

Boston · Massachusetts · United States

3 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
33

Centre Jean Perrin

Clermont-Ferrand · Puy-de-Dôme · France

3 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
34

Samsung Medical Center

Seoul · South Korea

3 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
35

MidLantic Urology

Bala-Cynwyd · Pennsylvania · United States

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
36

MD Anderson Cancer Center

Houston · Texas · United States

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
37

Yokohama City University Medical Center

Yokohama · Japan

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
38

Severance Hospital Yonsei University Health System

Seoul · South Korea

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
39

The Catholic University of Korea Seoul St Marys Hospital

Seoul · South Korea

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
40

Hosp. de Jerez de La Frontera

Jerez de la Frontera · Spain

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
41

Hosp. Univ. Ramon Y Cajal

Madrid · Spain

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
42

Hosp Virgen de La Victoria

Málaga · Spain

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
43

Taichung Veterans General Hospital

Taichung · Taiwan

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
44

Tungs' Taichung MetroHarbor Hospital

Taichung · Taiwan

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
45

National Taiwan University Hospital

Taipei · Taiwan

3 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
46

Mayo Clinic Hospital in Arizona

Phoenix · Arizona · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
47

Mayo Clinic in Florida

Jacksonville · Florida · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
At-home cancer drug treatment delivery improves satisfaction versus traditional clinic visits.
Mayo ClinicPh 2RecruitingNCT07285044 ↗
48

University of Kansas Cancer Center

Kansas City · Kansas · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
49

Siteman Cancer Center at Christian Hospital

St Louis · Missouri · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
50

University of Oklahoma Health Sciences Center

Oklahoma City · Oklahoma · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
51

UT Southwestern/Simmons Cancer Center-Dallas

Dallas · Texas · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
52

UT Southwestern/Simmons Cancer Center-Fort Worth

Fort Worth · Texas · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
53

UT Southwestern Clinical Center at Richardson/Plano

Richardson · Texas · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
54

University of Wisconsin Carbone Cancer Center - University Hospital

Madison · Wisconsin · United States

3 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
55

Centre Georges Francois Leclerc

Dijon · France

3 trials
Darolutamide drug plus high-dose focused radiation therapy for localized prostate cancer with high relapse risk.
UNICANCERPh 3RecruitingNCT06625970 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
56

University of Kansas Clinical Research Center

Fairway · Kansas · United States

3 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
57

East Jefferson General Hospital

Metairie · Louisiana · United States

3 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
58

University of Kansas Cancer Center - Lee's Summit

Lee's Summit · Missouri · United States

3 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
59

Memorial Sloan Kettering Monmouth

Middletown · New Jersey · United States

3 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Ultra-hypofractionated radiotherapy targets the prostate and dominant lesion as definitive treatment for intermediate-risk prostate cancer.
Memorial Sloan Kettering Cancer CenterPh 1NCT03269422 ↗
60

Vanderbilt University/Ingram Cancer Center

Nashville · Tennessee · United States

3 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
61

Moffitt Cancer Center

Tampa · Florida · United States

3 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
62

Beth Israel Deaconess Medical Center

Boston · Massachusetts · United States

3 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
63

Dana-Farber Cancer Institute

Boston · Massachusetts · United States

3 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
64

VCU Massey Comprehensive Cancer Center

Richmond · Virginia · United States

3 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
65

Rutgers Cancer Institute of New Jersey

New Brunswick · New Jersey · United States

3 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
66

Fred Hutchinson Cancer Center

Seattle · Washington · United States

3 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
67

Massachusetts General Hospital

Boston · Massachusetts · United States

2 trials
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1Opening soonNCT07719361 ↗
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
68

START New Jersey

East Brunswick · New Jersey · United States

2 trials
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1RecruitingNCT07719361 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
69

Tennessee Oncology

Nashville · Tennessee · United States

2 trials
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1Opening soonNCT07719361 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
70

NEXT Oncology

San Antonio · Texas · United States

2 trials
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1Opening soonNCT07719361 ↗
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
71

University of Texas MD Anderson Cancer Center

Houston · Texas · United States

2 trials
Fluorthanatrace imaging and blood tests to predict treatment response to PARP inhibitors in metastatic prostate cancer.
Washington University School of MedicinePh 2NCT07723651 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
72

Urology Centers Of Alabama

Homewood · Alabama · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
73

Arkansas Urology

Little Rock · Arkansas · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
74

Sansum Clinic Pharm

Santa Barbara · California · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
75

Advanced Urology Institute

Daytona Beach · Florida · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
76

Chesapeake Urology Research Associates

Towson · Maryland · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
77

Michigan Institute of Urology

Troy · Michigan · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
78

Helios Clinical Research, LLC

Middleburg Heights · Ohio · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
79

University of Pittsburgh Medical Center

Pittsburgh · Pennsylvania · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
80

VA Pittsburgh

Pittsburgh · Pennsylvania · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
81

Urology Associates

Nashville · Tennessee · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
82

UT Southwestern Medical Center

Dallas · Texas · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
83

Houston Metro Urology

Houston · Texas · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
84

Virginia Oncology Associates

Norfolk · Virginia · United States

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
85

Fundacao Pio XII

Barretos · Brazil

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
86

Ministerio da Saude Instituto Nacional do Cancer

Rio de Janeiro · Brazil

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
87

Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo

São Paulo · Brazil

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
88

Southern Alberta Institute of Urology / Prostate Cancer Centre

Calgary · Alberta · Canada

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
89

Nova Scotia Health Authority

Halifax · Nova Scotia · Canada

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
90

Princess Margaret Hospital

Toronto · Ontario · Canada

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
91

CHU de Quebec Universite Laval Hopital de l Enfant Jesus

Québec · Quebec · Canada

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
92

Chu Rennes Hopital Pontchaillou

Rennes · France

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
93

Gustave Roussy

Villejuif · France

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
94

Universitaetsklinikum der RWTH Aachen

Aachen · Germany

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
95

Universitaetsklinikum Koelnt

Cologne · Germany

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
96

Universitatsklinikum Schleswig Holstein Campus Lubeck

Lübeck · Germany

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
97

Studienpraxis Urologie Nurtingen

Nürtingen · Germany

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
98

Consultorio de Especialidad en Urologia Privado

Durango · Mexico

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
99

Centrum Onkologii im Prof F Lukaszczyka

Bydgoszcz · Poland

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
100

Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O

Warsaw · Poland

2 trials
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
101

Nebraska Cancer Specialists

Omaha · Nebraska · United States

2 trials
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
102

Novartis Investigative Site

Madrid · Spain

2 trials
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
103

Emory University

Atlanta · Georgia · United States

2 trials
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
104

Karmanos Cancer Institute

Detroit · Michigan · United States

2 trials
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
105

Sarah Cannon Research Institute

Nashville · Tennessee · United States

2 trials
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
106

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles · California · United States

2 trials
New PET imaging tracer (68Ga-FAPi-46) tested to map where it accumulates in solid and blood cancers.
Jonsson Comprehensive Cancer CenterPh 1NCT07118176 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2CompletedNCT03866382 ↗
107

Advent Health

Orlando · Florida · United States

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
108

Virginia Cancer Specialists

Fairfax · Virginia · United States

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
109

Institut Gustave Roussy

Villejuif · Val-de-Marne · France

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
110

ASST Grande Ospedale Metropolitano Niguarda

Milan · Lombardy · Italy

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
111

Fondazione IRCCS Istituto Nazionale Dei Tumori

Milan · Lombardy · Italy

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
112

Istituto Europeo Di Oncologia

Milan · Lombardy · Italy

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
113

Istituto Clinico Humanitas

Rozzano · Lombardy · Italy

2 trials
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
114

Cedars Sinai Medical Center

Los Angeles · California · United States

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
115

Mayo Clinic - Division Of Hematology/oncology

Jacksonville · Florida · United States

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
116

Emory University Winship Cancer Institute

Atlanta · Georgia · United States

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
117

Urology of Virginia, PLCC

Virginia Beach · Virginia · United States

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
118

Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

Córdoba · Argentina

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
119

St Vincent s Hospital Sydney

Darlinghurst · Australia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
120

Sydney Adventist Hospital

Wahroonga · Australia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
121

Princess Alexandra Hospital

Woolloongabba · Australia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
122

Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge

Goiânia · Brazil

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
123

Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda

Ijuí · Brazil

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
124

Irmandade Santa Casa de Misericordia de Porto Alegre

Porto Alegre · Brazil

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
125

Universidade do Estado do Rio de Janeiro - UERJ

Rio de Janeiro · Brazil

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
126

Princess Margaret Cancer Centre University Health Network

Toronto · Ontario · Canada

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
127

Fakultni nemocnice Hradec Kralove

Hradec Králove · Czechia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
128

Krajská nemocnice Liberec

Liberec · Czechia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
129

Uromedical Center s.r.o.

Olomouc · Czechia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
130

Fakultni nemocnice Plzen, Urologicka klinika

Pilsen · Czechia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
131

Asaf Harofe Medical Center

Beer Yaakov · Israel

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
132

Rambam Health Care Campus

Haifa · Israel

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
133

Rabin Medical Center

Petah Tikva · Israel

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
134

Ospedale San Raffaele

Milan · Italy

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
135

Kanazawa University Hospital

Kanazawa · Japan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
136

Kyoto University Hospital

Kyoto · Japan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
137

National Hospital Organization Shikoku Cancer Center

Matsuyama · Japan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
138

Osaka International Cancer Institute

Osaka · Japan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
139

Toho University Sakura Medical Center

Sakura · Japan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
140

Yamaguchi University Hospital

Ube · Japan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
141

Antoni van Leeuwenhoek

Amsterdam · Netherlands

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
142

St. Antonius Ziekenhuis (St. Antonius Hospital)

Nieuwegein · Netherlands

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
143

Szpital Uniwersytecki NR 1 IM Dr Antoniego Jurasza

Bydgoszcz · Poland

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
144

Altai Regional Oncology Dispensary

Barnaul · Russia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
145

Clinical Oncology Dispensary

Omsk · Russia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
146

Medical-sanitary unit 'Neftyanik'

Tyumen · Russia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
147

Vologda Regional Oncological Dispensary

Vologda · Russia

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
148

Chonnam National University Hospital

Gwangju · South Korea

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
149

Hosp Univ Vall D Hebron

Barcelona · Spain

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
150

Hosp. Univ. 12 de Octubre

Madrid · Spain

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
151

Hosp. Univ. Marques de Valdecilla

Santander · Spain

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
152

Kaohsiung Medical University Chung Ho Memorial Hospital

Kaohsiung City · Taiwan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
153

China Medical University Hospital

Taichung · Taiwan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
154

Chi Mei Medical Center Yong Kang

Tainan · Taiwan

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
155

New Cross Hospital

Wolverhampton · United Kingdom

2 trials
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
156

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange · California · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
157

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables · Florida · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
158

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach · Florida · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
159

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami · Florida · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
160

Memorial Hospital East

Shiloh · Illinois · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
161

UT Southwestern Simmons Cancer Center - RedBird

Dallas · Texas · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
162

University of Virginia Cancer Center

Charlottesville · Virginia · United States

2 trials
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
163

Hia Begin

Saint-Mandé · France

2 trials
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
164

Clinique PASTEUR

Toulouse · France

2 trials
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
165

Oregon Health And Science University

Portland · Oregon · United States

2 trials
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
166

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou · China

2 trials
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
167

University of California San Francisco

San Francisco · California · United States

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
168

Bay Pines VA Healthcare System

Bay Pines · Florida · United States

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
169

University of Kansas Medical Center

Kansas City · Kansas · United States

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
170

Oregon Urology Institute

Springfield · Oregon · United States

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
171

Utah Cancer Specialists

Salt Lake City · Utah · United States

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
172

Fiona Stanley Hospital

Murdoch · Australia

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
173

AZ Maria Middelares

Ghent · Belgium

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
174

Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia

Joinville · Brazil

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
175

Fundacao Antonio Prudente A C Camargo Cancer Center

São Paulo · Brazil

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
176

Chongqing University Cancer Hospital

Chongqing · China

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
177

Fudan University Shanghai Cancer Center

Shanghai · China

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
178

Urologicum Duisburg

Duisburg · Germany

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
179

Universitaetsklinikum Muenster

Münster · Germany

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
180

Fondazione Policlinico Universitario A Gemelli IRCCS

Roma · Italy

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
181

Erasmus MC

Rotterdam · Netherlands

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
182

Chungnam National University Hospital

Daejeon · South Korea

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
183

Taipei Veterans General Hospital

Taipei · Taiwan

2 trials
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
184

Virginia Mason Medical Center

Seattle · Washington · United States

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
185

Site DE49004

Nürtingen · Baden-Wurttemberg · Germany

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
186

Site IT39005

Roma · Italy

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
187

Nippon Medical School Hospital

Bunkyo-ku · Tokyo · Japan

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
188

Harasanshin hospital

Fukuoka · Japan

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
189

Site KR82007

Seoul · South Korea

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
190

Site KR82002

Seoul · South Korea

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
191

Site KR82003

Seoul · South Korea

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
192

Site KR82004

Seoul · South Korea

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
193

Site ES34001

Madrid · Spain

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
194

Site TW88603

Kaohsiung City · Taiwan

2 trials
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
195

University of Alabama at Birmingham Cancer Center

Birmingham · Alabama · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
196

Anchorage Associates in Radiation Medicine

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
197

Anchorage Radiation Therapy Center

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
198

Alaska Breast Care and Surgery LLC

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
199

Alaska Oncology and Hematology LLC

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
200

Alaska Women's Cancer Care

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
201

Anchorage Oncology Centre

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
202

Katmai Oncology Group

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
203

Providence Alaska Medical Center

Anchorage · Alaska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
204

Kingman Regional Medical Center

Kingman · Arizona · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
205

Cancer Center at Saint Joseph's

Phoenix · Arizona · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
206

Mayo Clinic in Arizona

Scottsdale · Arizona · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
207

Mercy Hospital Fort Smith

Fort Smith · Arkansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
208

CHI Saint Vincent Cancer Center Hot Springs

Hot Springs · Arkansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
209

Mission Hope Medical Oncology - Arroyo Grande

Arroyo Grande · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
210

PCR Oncology

Arroyo Grande · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
211

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
212

Community Cancer Institute

Clovis · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
213

University Oncology Associates

Clovis · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
214

Epic Care-Dublin

Dublin · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
215

Bay Area Breast Surgeons Inc

Emeryville · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
216

Epic Care Partners in Cancer Care

Emeryville · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
217

Marin Cancer Care Inc

Greenbrae · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
218

Los Angeles General Medical Center

Los Angeles · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
219

USC / Norris Comprehensive Cancer Center

Los Angeles · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
220

Contra Costa Regional Medical Center

Martinez · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
221

USC Norris Oncology/Hematology-Newport Beach

Newport Beach · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
222

Alta Bates Summit Medical Center - Summit Campus

Oakland · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
223

Bay Area Tumor Institute

Oakland · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
224

Pacific Central Coast Health Center-San Luis Obispo

San Luis Obispo · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
225

Mission Hope Medical Oncology - Santa Maria

Santa Maria · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
226

Epic Care Cyberknife Center

Walnut Creek · California · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
227

Penrose-Saint Francis Healthcare

Colorado Springs · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
228

Rocky Mountain Cancer Centers-Penrose

Colorado Springs · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
229

AdventHealth Porter

Denver · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
230

CommonSpirit Cancer Center Mercy

Durango · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
231

Mercy Medical Center

Durango · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
232

CommonSpirit Saint Anthony Hospital Cancer Center

Lakewood · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
233

AdventHealth Littleton

Littleton · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
234

Longmont United Hospital

Longmont · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
235

Rocky Mountain Cancer Centers-Longmont

Longmont · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
236

AdventHealth Parker

Parker · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
237

Saint Mary Corwin Medical Center

Pueblo · Colorado · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
238

MedStar Georgetown University Hospital

Washington D.C. · District of Columbia · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
239

Mount Sinai Comprehensive Cancer Center at Aventura

Aventura · Florida · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
240

Holy Cross Hospital

Fort Lauderdale · Florida · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
241

Mount Sinai Medical Center

Miami Beach · Florida · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
242

Orlando Health Cancer Institute

Orlando · Florida · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
243

Emory University Hospital Midtown

Atlanta · Georgia · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
244

Emory University Hospital/Winship Cancer Institute

Atlanta · Georgia · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
245

Emory Saint Joseph's Hospital

Atlanta · Georgia · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
246

Saint Alphonsus Cancer Care Center-Boise

Boise · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
247

Saint Luke's Cancer Institute - Boise

Boise · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
248

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
249

Kootenai Health - Coeur d'Alene

Coeur d'Alene · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
250

Walter Knox Memorial Hospital

Emmett · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
251

Saint Luke's Cancer Institute - Fruitland

Fruitland · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
252

Idaho Urologic Institute-Meridian

Meridian · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
253

Saint Luke's Cancer Institute - Meridian

Meridian · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
254

Saint Alphonsus Cancer Care Center-Nampa

Nampa · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
255

Saint Luke's Cancer Institute - Nampa

Nampa · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
256

Kootenai Clinic Cancer Services - Post Falls

Post Falls · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
257

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
258

Saint Luke's Cancer Institute - Twin Falls

Twin Falls · Idaho · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
259

OSF Saint Anthony's Health Center

Alton · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
260

Rush-Copley Medical Center

Aurora · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
261

Illinois CancerCare-Bloomington

Bloomington · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
262

Illinois CancerCare-Canton

Canton · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
263

Memorial Hospital of Carbondale

Carbondale · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
264

SIH Cancer Institute

Carterville · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
265

Illinois CancerCare-Carthage

Carthage · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
266

Northwestern University

Chicago · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
267

Rush MD Anderson Cancer Center

Chicago · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
268

University of Illinois

Chicago · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
269

University of Chicago Comprehensive Cancer Center

Chicago · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
270

Carle at The Riverfront

Danville · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
271

Cancer Care Specialists of Illinois - Decatur

Decatur · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
272

Decatur Memorial Hospital

Decatur · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
273

Illinois CancerCare-Dixon

Dixon · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
274

Carle Physician Group-Effingham

Effingham · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
275

Crossroads Cancer Center

Effingham · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
276

Illinois CancerCare-Eureka

Eureka · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
277

Illinois CancerCare-Galesburg

Galesburg · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
278

Western Illinois Cancer Treatment Center

Galesburg · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
279

Illinois CancerCare-Kewanee Clinic

Kewanee · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
280

Northwestern Medicine Lake Forest Hospital

Lake Forest · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
281

Illinois CancerCare-Macomb

Macomb · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
282

Carle Physician Group-Mattoon/Charleston

Mattoon · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
283

Loyola University Medical Center

Maywood · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
284

Marjorie Weinberg Cancer Center at Loyola-Gottlieb

Melrose Park · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
285

SSM Health Good Samaritan

Mount Vernon · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
286

UC Comprehensive Cancer Center at Silver Cross

New Lenox · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
287

Cancer Care Center of O'Fallon

O'Fallon · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
288

University of Chicago Medicine-Orland Park

Orland Park · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
289

Illinois CancerCare-Ottawa Clinic

Ottawa · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
290

Illinois CancerCare-Pekin

Pekin · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
291

Illinois CancerCare-Peoria

Peoria · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
292

Methodist Medical Center of Illinois

Peoria · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
293

Illinois CancerCare-Peru

Peru · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
294

Valley Radiation Oncology

Peru · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
295

Illinois CancerCare-Princeton

Princeton · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
296

Southern Illinois University School of Medicine

Springfield · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
297

Springfield Clinic

Springfield · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
298

Springfield Memorial Hospital

Springfield · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
299

Southwest Illinois Health Services LLP

Swansea · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
300

Carle Cancer Center

Urbana · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
301

The Carle Foundation Hospital

Urbana · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
302

Illinois CancerCare - Washington

Washington · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
303

Rush-Copley Healthcare Center

Yorkville · Illinois · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
304

Reid Health

Richmond · Indiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
305

Mary Greeley Medical Center

Ames · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
306

McFarland Clinic - Ames

Ames · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
307

McFarland Clinic - Boone

Boone · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
308

Mercy Cancer Center-West Lakes

Clive · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
309

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
310

Alegent Health Mercy Hospital

Council Bluffs · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
311

Greater Regional Medical Center

Creston · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
312

Iowa Methodist Medical Center

Des Moines · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
313

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
314

Mercy Medical Center - Des Moines

Des Moines · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
315

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
316

McFarland Clinic - Trinity Cancer Center

Fort Dodge · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
317

McFarland Clinic - Jefferson

Jefferson · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
318

McFarland Clinic - Marshalltown

Marshalltown · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
319

Mercy Medical Center-West Lakes

West Des Moines · Iowa · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
320

Central Care Cancer Center - Garden City

Garden City · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
321

Central Care Cancer Center - Great Bend

Great Bend · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
322

HaysMed

Hays · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
323

Lawrence Memorial Hospital

Lawrence · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
324

The University of Kansas Cancer Center - Olathe

Olathe · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
325

Mercy Hospital Pittsburg

Pittsburg · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
326

Salina Regional Health Center

Salina · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
327

University of Kansas Health System Saint Francis Campus

Topeka · Kansas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
328

CommonSpirit Saint Joseph Hospital - Bardstown

Bardstown · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
329

Commonwealth Cancer Center-Corbin

Corbin · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
330

Saint Joseph Radiation Oncology Resource Center

Lexington · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
331

CommonSpirit Saint Joseph Medical Center - East Lexington

Lexington · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
332

University of Kentucky/Markey Cancer Center

Lexington · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
333

CommonSpirit Saint Joseph Hospital London

London · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
334

Jewish Hospital

Louisville · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
335

Saints Mary and Elizabeth Hospital

Louisville · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
336

UofL Health Medical Center Northeast

Louisville · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
337

Jewish Hospital Medical Center South

Shepherdsville · Kentucky · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
338

Hematology/Oncology Clinic PLLC

Baton Rouge · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
339

Louisiana Hematology Oncology Associates LLC

Baton Rouge · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
340

Ochsner High Grove

Baton Rouge · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
341

Northshore Oncology Associates-Covington

Covington · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
342

Ochsner Medical Center Kenner

Kenner · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
343

Louisiana State University Health Science Center

New Orleans · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
344

Tulane University School of Medicine

New Orleans · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
345

Ochsner Medical Center Jefferson

New Orleans · Louisiana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
346

Greater Baltimore Medical Center

Baltimore · Maryland · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
347

FMH James M Stockman Cancer Institute

Frederick · Maryland · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
348

Lahey Clinic

Burlington · Massachusetts · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
349

Lahey Clinic Peabody

Peabody · Massachusetts · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
350

Mercy Medical Center

Springfield · Massachusetts · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
351

Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care

Winchester · Massachusetts · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
352

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
353

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
354

Trinity Health Medical Center - Brighton

Brighton · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
355

Henry Ford Cancer Institute-Downriver

Brownstown · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
356

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
357

Trinity Health Medical Center - Canton

Canton · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
358

Caro Cancer Center

Caro · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
359

Chelsea Hospital

Chelsea · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
360

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
361

Hematology Oncology Consultants-Clarkston

Clarkston · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
362

Newland Medical Associates-Clarkston

Clarkston · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
363

Henry Ford Macomb Hospital-Clinton Township

Clinton Township · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
364

Henry Ford Medical Center-Fairlane

Dearborn · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
365

Henry Ford Hospital

Detroit · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
366

Henry Ford Health Saint John Hospital

Detroit · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
367

Henry Ford River District Hospital

East China Township · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
368

Cancer Hematology Centers - Flint

Flint · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
369

Genesee Hematology Oncology PC

Flint · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
370

Genesys Hurley Cancer Institute

Flint · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
371

Hurley Medical Center

Flint · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
372

Henry Ford Saint John Hospital - Academic

Grosse Pointe Woods · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
373

Henry Ford Saint John Hospital - Breast

Grosse Pointe Woods · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
374

Henry Ford Saint John Hospital - Van Elslander

Grosse Pointe Woods · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
375

Allegiance Health

Jackson · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
376

University of Michigan Health - Sparrow Lansing

Lansing · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
377

Hope Cancer Clinic

Livonia · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
378

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
379

Henry Ford Saint John Hospital - Macomb Medical

Macomb · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
380

Henry Ford Warren Hospital - Breast Macomb

Macomb · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
381

Saint Mary's Oncology/Hematology Associates of Marlette

Marlette · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
382

Henry Ford Medical Center-Columbus

Novi · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
383

Hope Cancer Center

Pontiac · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
384

Michigan Healthcare Professionals Pontiac

Pontiac · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
385

Newland Medical Associates-Pontiac

Pontiac · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
386

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
387

Huron Medical Center PC

Port Huron · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
388

Lake Huron Medical Center

Port Huron · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
389

Henry Ford Rochester Hospital

Rochester Hills · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
390

MyMichigan Medical Center Saginaw

Saginaw · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
391

Oncology Hematology Associates of Saginaw Valley PC

Saginaw · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
392

Henry Ford Macomb Health Center - Shelby Township

Shelby · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
393

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
394

MyMichigan Medical Center Tawas

Tawas City · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
395

Advanced Breast Care Center PLLC

Warren · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
396

Henry Ford Health Warren Hospital

Warren · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
397

Henry Ford Madison Heights Hospital - Breast

Warren · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
398

Henry Ford Warren Hospital - GLCMS

Warren · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
399

Macomb Hematology Oncology PC

Warren · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
400

Henry Ford West Bloomfield Hospital

West Bloomfield · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
401

Saint Mary's Oncology/Hematology Associates of West Branch

West Branch · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
402

Henry Ford Wyandotte Hospital

Wyandotte · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
403

Huron Gastroenterology PC

Ypsilanti · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
404

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti · Michigan · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
405

Riverwood Healthcare Center

Aitkin · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
406

Essentia Health Saint Joseph's Medical Center

Brainerd · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
407

Fairview Ridges Hospital

Burnsville · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
408

Minnesota Oncology - Burnsville

Burnsville · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
409

Cambridge Medical Center

Cambridge · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
410

Mercy Hospital

Coon Rapids · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
411

Essentia Health - Deer River Clinic

Deer River · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
412

Essentia Health Saint Mary's - Detroit Lakes Clinic

Detroit Lakes · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
413

Essentia Health Cancer Center

Duluth · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
414

Essentia Health Saint Mary's Medical Center

Duluth · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
415

Miller-Dwan Hospital

Duluth · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
416

Fairview Southdale Hospital

Edina · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
417

Lake Region Healthcare Corporation-Cancer Care

Fergus Falls · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
418

Essentia Health - Fosston

Fosston · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
419

Unity Hospital

Fridley · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
420

Essentia Health Hibbing Clinic

Hibbing · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
421

Fairview Clinics and Surgery Center Maple Grove

Maple Grove · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
422

Minnesota Oncology Hematology PA-Maplewood

Maplewood · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
423

Saint John's Hospital - Healtheast

Maplewood · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
424

Abbott-Northwestern Hospital

Minneapolis · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
425

Hennepin County Medical Center

Minneapolis · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
426

Health Partners Inc

Minneapolis · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
427

Monticello Cancer Center

Monticello · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
428

New Ulm Medical Center

New Ulm · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
429

Essentia Health - Park Rapids

Park Rapids · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
430

Fairview Northland Medical Center

Princeton · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
431

North Memorial Medical Health Center

Robbinsdale · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
432

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
433

Regions Hospital

Saint Paul · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
434

United Hospital

Saint Paul · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
435

Essentia Health Sandstone

Sandstone · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
436

Saint Francis Regional Medical Center

Shakopee · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
437

Lakeview Hospital

Stillwater · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
438

Essentia Health Virginia Clinic

Virginia · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
439

Ridgeview Medical Center

Waconia · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
440

Rice Memorial Hospital

Willmar · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
441

Minnesota Oncology Hematology PA-Woodbury

Woodbury · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
442

Fairview Lakes Medical Center

Wyoming · Minnesota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
443

University of Mississippi Medical Center

Jackson · Mississippi · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
444

Central Care Cancer Center - Bolivar

Bolivar · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
445

Parkland Health Center-Bonne Terre

Bonne Terre · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
446

Cox Cancer Center Branson

Branson · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
447

Mercy Cancer Center - Cape Girardeau

Cape Girardeau · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
448

Saint Francis Medical Center

Cape Girardeau · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
449

Parkland Health Center - Farmington

Farmington · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
450

MU Health Care Goldschmidt Cancer Center

Jefferson City · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
451

Freeman Health System

Joplin · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
452

Mercy Hospital Joplin

Joplin · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
453

University Health Truman Medical Center

Kansas City · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
454

Mercy Clinic-Rolla-Cancer and Hematology

Rolla · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
455

Phelps Health Delbert Day Cancer Institute

Rolla · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
456

Heartland Regional Medical Center

Saint Joseph · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
457

Sainte Genevieve County Memorial Hospital

Sainte Genevieve · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
458

Mercy Hospital Springfield

Springfield · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
459

CoxHealth South Hospital

Springfield · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
460

Mercy Infusion Center - Chippewa

St Louis · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
461

Mercy Hospital South

St Louis · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
462

Missouri Baptist Medical Center

St Louis · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
463

Mercy Hospital Saint Louis

St Louis · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
464

Missouri Baptist Sullivan Hospital

Sullivan · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
465

BJC Outpatient Center at Sunset Hills

Sunset Hills · Missouri · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
466

Community Hospital of Anaconda

Anaconda · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
467

Billings Clinic Cancer Center

Billings · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
468

Bozeman Health Deaconess Hospital

Bozeman · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
469

Benefis Sletten Cancer Institute

Great Falls · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
470

Saint Peter's Community Hospital

Helena · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
471

Logan Health Medical Center

Kalispell · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
472

Saint Patrick Hospital - Community Hospital

Missoula · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
473

Community Medical Center

Missoula · Montana · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
474

Nebraska Medicine-Bellevue

Bellevue · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
475

Nebraska Cancer Specialists/Oncology Hematology West PC

Grand Island · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
476

CHI Health Good Samaritan

Kearney · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
477

Saint Elizabeth Regional Medical Center

Lincoln · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
478

Nebraska Cancer Specialists/Oncology Hematology West PC - MECC

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
479

Nebraska Methodist Hospital

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
480

Oncology Associates PC

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
481

Nebraska Medicine-Village Pointe

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
482

Alegent Health Immanuel Medical Center

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
483

Alegent Health Bergan Mercy Medical Center

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
484

Alegent Health Lakeside Hospital

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
485

University of Nebraska Medical Center

Omaha · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
486

Midlands Community Hospital

Papillion · Nebraska · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
487

Carson Tahoe Regional Medical Center

Carson City · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
488

Cancer and Blood Specialists-Henderson

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
489

Comprehensive Cancer Centers of Nevada - Henderson

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
490

Comprehensive Cancer Centers of Nevada-Horizon Ridge

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
491

Las Vegas Cancer Center-Henderson

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
492

Comprehensive Cancer Centers of Nevada-Southeast Henderson

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
493

Las Vegas Urology - Green Valley

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
494

Las Vegas Urology - Pebble

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
495

Oncology Las Vegas - Henderson

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
496

Urology Specialists of Nevada - Green Valley

Henderson · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
497

Las Vegas Urology - Pecos

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
498

Desert West Surgery

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
499

OptumCare Cancer Care at Charleston

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
500

University Medical Center of Southern Nevada

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
501

Cancer and Blood Specialists-Shadow

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
502

Radiation Oncology Centers of Nevada Central

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
503

Urology Specialists of Nevada - Central

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
504

HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
505

Sunrise Hospital and Medical Center

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
506

HealthCare Partners Medical Group Oncology/Hematology-San Martin

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
507

Las Vegas Prostate Cancer Center

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
508

Las Vegas Urology - Sunset

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
509

Urology Specialists of Nevada - Southwest

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
510

Radiation Oncology Centers of Nevada Southeast

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
511

Ann M Wierman MD LTD

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
512

Cancer and Blood Specialists-Tenaya

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
513

Comprehensive Cancer Centers of Nevada - Northwest

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
514

HealthCare Partners Medical Group Oncology/Hematology-Tenaya

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
515

Las Vegas Urology - Cathedral Rock

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
516

Las Vegas Urology - Smoke Ranch

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
517

Oncology Las Vegas - Tenaya

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
518

OptumCare Cancer Care at MountainView

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
519

Urology Specialists of Nevada - Northwest

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
520

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
521

Comprehensive Cancer Centers of Nevada - Town Center

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
522

Comprehensive Cancer Centers of Nevada-Summerlin

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
523

Summerlin Hospital Medical Center

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
524

Las Vegas Cancer Center-Medical Center

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
525

HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
526

Comprehensive Cancer Centers of Nevada - Central Valley

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
527

OptumCare Cancer Care at Fort Apache

Las Vegas · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
528

Hope Cancer Care of Nevada-Pahrump

Pahrump · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
529

Renown Regional Medical Center

Reno · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
530

Saint Mary's Regional Medical Center

Reno · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
531

Radiation Oncology Associates

Reno · Nevada · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
532

Memorial Sloan Kettering Bergen

Montvale · New Jersey · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Ultra-hypofractionated radiotherapy targets the prostate and dominant lesion as definitive treatment for intermediate-risk prostate cancer.
Memorial Sloan Kettering Cancer CenterPh 1NCT03269422 ↗
533

Roswell Park Cancer Institute

Buffalo · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
534

Memorial Sloan Kettering Commack

Commack · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Ultra-hypofractionated radiotherapy targets the prostate and dominant lesion as definitive treatment for intermediate-risk prostate cancer.
Memorial Sloan Kettering Cancer CenterPh 1NCT03269422 ↗
535

Memorial Sloan Kettering Westchester

Harrison · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
536

Northwell Health/Center for Advanced Medicine

Lake Success · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
537

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
538

NYP/Weill Cornell Medical Center

New York · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
539

University of Rochester

Rochester · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
540

State University of New York Upstate Medical University

Syracuse · New York · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
541

UNC Lineberger Comprehensive Cancer Center

Chapel Hill · North Carolina · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
542

Margaret R Pardee Memorial Hospital

Hendersonville · North Carolina · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
543

Essentia Health Cancer Center-South University Clinic

Fargo · North Dakota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
544

Essentia Health - Jamestown Clinic

Jamestown · North Dakota · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
545

Indu and Raj Soin Medical Center

Beavercreek · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
546

Strecker Cancer Center-Belpre

Belpre · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
547

Saint Elizabeth Boardman Hospital

Boardman · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
548

Dayton Physicians LLC-Miami Valley South

Centerville · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
549

Miami Valley Hospital South

Centerville · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
550

Adena Regional Medical Center

Chillicothe · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
551

Good Samaritan Hospital - Cincinnati

Cincinnati · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
552

Oncology Hematology Care Inc-Kenwood

Cincinnati · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
553

Bethesda North Hospital

Cincinnati · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
554

TriHealth Cancer Institute-Westside

Cincinnati · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
555

TriHealth Cancer Institute-Anderson

Cincinnati · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
556

Mount Carmel East Hospital

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
557

Columbus Oncology and Hematology Associates Inc

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
558

Riverside Methodist Hospital

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
559

Grant Medical Center

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
560

The Mark H Zangmeister Center

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
561

Mount Carmel Health Center West

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
562

Doctors Hospital

Columbus · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
563

Good Samaritan Hospital - Dayton

Dayton · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
564

Miami Valley Hospital

Dayton · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
565

Dayton Physician LLC - Englewood

Dayton · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
566

Miami Valley Hospital North

Dayton · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
567

Delaware Health Center-Grady Cancer Center

Delaware · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
568

Grady Memorial Hospital

Delaware · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
569

Dublin Methodist Hospital

Dublin · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
570

Armes Family Cancer Center

Findlay · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
571

Blanchard Valley Hospital

Findlay · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
572

Orion Cancer Care

Findlay · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
573

Atrium Medical Center-Middletown Regional Hospital

Franklin · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
574

Dayton Physicians LLC-Atrium

Franklin · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
575

Dayton Physicians LLC-Wayne

Greenville · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
576

Wayne Hospital

Greenville · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
577

Mount Carmel Grove City Hospital

Grove City · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
578

Greater Dayton Cancer Center

Kettering · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
579

First Dayton Cancer Care

Kettering · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
580

Kettering Medical Center

Kettering · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
581

Fairfield Medical Center

Lancaster · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
582

Saint Rita's Medical Center

Lima · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
583

Marietta Memorial Hospital

Marietta · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
584

OhioHealth Marion General Hospital

Marion · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
585

Knox Community Hospital

Mount Vernon · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
586

Licking Memorial Hospital

Newark · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
587

Newark Radiation Oncology

Newark · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
588

Mercy Health - Perrysburg Hospital

Perrysburg · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
589

Southern Ohio Medical Center

Portsmouth · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
590

Springfield Regional Cancer Center

Springfield · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
591

Springfield Regional Medical Center

Springfield · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
592

Mercy Health - Saint Vincent Hospital

Toledo · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
593

Mercy Health - Saint Anne Hospital

Toledo · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
594

Dayton Physicians LLC - Troy

Troy · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
595

Upper Valley Medical Center

Troy · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
596

Saint Joseph Warren Hospital

Warren · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
597

Saint Ann's Hospital

Westerville · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
598

Saint Elizabeth Youngstown Hospital

Youngstown · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
599

Genesis Healthcare System Cancer Care Center

Zanesville · Ohio · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
600

Cancer Centers of Southwest Oklahoma Research

Lawton · Oklahoma · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
601

Mercy Hospital Oklahoma City

Oklahoma City · Oklahoma · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
602

Oklahoma Cancer Specialists and Research Institute-Tulsa

Tulsa · Oklahoma · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
603

Saint Alphonsus Cancer Care Center-Baker City

Baker City · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
604

Saint Charles Health System

Bend · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
605

Clackamas Radiation Oncology Center

Clackamas · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
606

Providence Cancer Institute Clackamas Clinic

Clackamas · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
607

Bay Area Hospital

Coos Bay · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
608

Providence Newberg Medical Center

Newberg · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
609

Saint Alphonsus Cancer Care Center-Ontario

Ontario · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
610

Providence Willamette Falls Medical Center

Oregon City · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
611

Providence Portland Medical Center

Portland · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
612

Providence Saint Vincent Medical Center

Portland · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
613

Saint Charles Health System-Redmond

Redmond · Oregon · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
614

Lehigh Valley Hospital-Cedar Crest

Allentown · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
615

Lehigh Valley Hospital - Muhlenberg

Bethlehem · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
616

Pocono Medical Center

East Stroudsburg · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
617

UPMC Hillman Cancer Center Erie

Erie · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
618

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
619

Lehigh Valley Hospital-Hazleton

Hazleton · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
620

Forbes Hospital

Monroeville · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
621

UPMC Hillman Cancer Center - Monroeville

Monroeville · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
622

Arnold Palmer Cancer Center Medical Oncology Norwin

N. Huntingdon · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
623

Allegheny Valley Hospital

Natrona Heights · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
624

Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
625

West Penn Hospital

Pittsburgh · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
626

UPMC-Passavant Hospital

Pittsburgh · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
627

UPMC-Saint Clair Hospital Cancer Center

Pittsburgh · Pennsylvania · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
628

Vanderbilt-Ingram Cancer Center Cool Springs

Franklin · Tennessee · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
629

Vanderbilt Breast Center at One Hundred Oaks

Nashville · Tennessee · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
630

Saint Joseph Regional Cancer Center

Bryan · Texas · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
631

Providence Regional Cancer System-Aberdeen

Aberdeen · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
632

Overlake Medical Center

Bellevue · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
633

PeaceHealth Saint Joseph Medical Center

Bellingham · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
634

Highline Medical Center-Main Campus

Burien · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
635

Providence Regional Cancer System-Centralia

Centralia · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
636

Swedish Cancer Institute-Edmonds

Edmonds · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
637

Saint Elizabeth Hospital

Enumclaw · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
638

Providence Regional Cancer Partnership

Everett · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
639

Saint Francis Hospital

Federal Way · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
640

Swedish Cancer Institute-Issaquah

Issaquah · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
641

Kadlec Clinic Hematology and Oncology

Kennewick · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
642

Providence Regional Cancer System-Lacey

Lacey · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
643

Saint Clare Hospital

Lakewood · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
644

PeaceHealth Saint John Medical Center

Longview · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
645

Harrison HealthPartners Hematology and Oncology-Poulsbo

Poulsbo · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
646

Valley Medical Center

Renton · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
647

Pacific Gynecology Specialists

Seattle · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
648

Swedish Medical Center-Ballard Campus

Seattle · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
649

Swedish Medical Center-Cherry Hill

Seattle · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
650

Swedish Medical Center-First Hill

Seattle · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
651

PeaceHealth United General Medical Center

Sedro-Woolley · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
652

Providence Regional Cancer System-Shelton

Shelton · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
653

Saint Joseph Medical Center Hematology and Oncology - Silverdale

Silverdale · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
654

Franciscan Research Center-Northwest Medical Plaza

Tacoma · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
655

Northwest Medical Specialties PLLC

Tacoma · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
656

PeaceHealth Southwest Medical Center

Vancouver · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
657

Providence Saint Mary Regional Cancer Center

Walla Walla · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
658

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
659

Providence Regional Cancer System-Yelm

Yelm · Washington · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
660

Duluth Clinic Ashland

Ashland · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
661

Northwest Wisconsin Cancer Center

Ashland · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
662

Aurora Cancer Care-Southern Lakes VLCC

Burlington · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
663

Aurora Saint Luke's South Shore

Cudahy · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
664

Marshfield Medical Center-EC Cancer Center

Eau Claire · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
665

Aurora Health Care Germantown Health Center

Germantown · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
666

Aurora Cancer Care-Grafton

Grafton · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
667

Aurora BayCare Medical Center

Green Bay · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
668

Aurora Cancer Care-Kenosha South

Kenosha · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
669

Aurora Bay Area Medical Group-Marinette

Marinette · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
670

Marshfield Medical Center-Marshfield

Marshfield · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
671

Aurora Cancer Care-Milwaukee

Milwaukee · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
672

Aurora Saint Luke's Medical Center

Milwaukee · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
673

Aurora Sinai Medical Center

Milwaukee · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
674

Marshfield Medical Center - Minocqua

Minocqua · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
675

ProHealth D N Greenwald Center

Mukwonago · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
676

Cancer Center of Western Wisconsin

New Richmond · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
677

ProHealth Oconomowoc Memorial Hospital

Oconomowoc · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
678

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
679

Aurora Cancer Care-Racine

Racine · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
680

Marshfield Medical Center-Rice Lake

Rice Lake · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
681

Vince Lombardi Cancer Clinic-Sheboygan

Sheboygan · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
682

Marshfield Medical Center-River Region at Stevens Point

Stevens Point · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
683

Aurora Medical Center in Summit

Summit · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
684

Vince Lombardi Cancer Clinic-Two Rivers

Two Rivers · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
685

ProHealth Waukesha Memorial Hospital

Waukesha · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
686

UW Cancer Center at ProHealth Care

Waukesha · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
687

Aurora Cancer Care-Milwaukee West

Wauwatosa · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
688

Aurora West Allis Medical Center

West Allis · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
689

Marshfield Medical Center - Weston

Weston · Wisconsin · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
690

Billings Clinic-Cody

Cody · Wyoming · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
691

Welch Cancer Center

Sheridan · Wyoming · United States

2 trials
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
692

UC San Diego Medical Center - Hillcrest

San Diego · California · United States

2 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
693

Massachusetts General Hospital Cancer Center

Boston · Massachusetts · United States

2 trials
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
694

New Mexico Oncology Hematology Consultants

Albuquerque · New Mexico · United States

2 trials
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
695

Tennessee Oncology Nashville

Nashville · Tennessee · United States

2 trials
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
696

The Second Hospital of Tianjin Medical University

Tianjin · Tianjin Municipality · China

2 trials
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
697

National Cancer Center Hospital East

Kashiwa · Chiba · Japan

2 trials
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
698

City of Hope Comprehensive Cancer Center

Duarte · California · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
699

UCHealth University of Colorado Hospital

Aurora · Colorado · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
700

Smilow Cancer Hospital-Derby Care Center

Derby · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
701

Smilow Cancer Hospital Care Center-Fairfield

Fairfield · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
702

Smilow Cancer Hospital Care Center - Guilford

Guilford · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
703

Smilow Cancer Hospital Care Center at Saint Francis

Hartford · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
704

Yale-New Haven Hospital North Haven Medical Center

North Haven · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
705

Smilow Cancer Hospital-Orange Care Center

Orange · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
706

Smilow Cancer Hospital-Torrington Care Center

Torrington · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
707

Smilow Cancer Hospital Care Center-Trumbull

Trumbull · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
708

Smilow Cancer Hospital-Waterbury Care Center

Waterbury · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
709

Smilow Cancer Hospital Care Center - Waterford

Waterford · Connecticut · United States

2 trials
Berzosertib and carboplatin with or without docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
National Cancer Institute (NCI)Ph 2NCT03517969 ↗
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
710

Universitaetsklinikum Essen

Essen · Germany

2 trials
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
711

University of Kansas Cancer Center-Overland Park

Overland Park · Kansas · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
712

University of Maryland/Greenebaum Cancer Center

Baltimore · Maryland · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
713

University of Kansas Cancer Center - North

Kansas City · Missouri · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
714

University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City · Missouri · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
715

Duke University Medical Center

Durham · North Carolina · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Olaparib combined with radium-223 treats men with advanced prostate cancer spread to bone.
National Cancer Institute (NCI)Ph 1 / Ph 2NCT03317392 ↗
716

Fox Chase Cancer Center

Philadelphia · Pennsylvania · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Study characterizes genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry.
Fox Chase Cancer CenterNCT05754658 ↗
717

Medical College of Wisconsin

Milwaukee · Wisconsin · United States

2 trials
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
718

Hopital Européen Georges Pompidou

Paris · France

1 trial
Large language models are compared against tumor boards for recommending cancer treatments using 100 standardized synthetic cases.
Assistance Publique - Hôpitaux de ParisRecruitingNCT07739121 ↗
719

Tampere University Hospital

Tampere · Finland

1 trial
A study explores vulnerability causes in 1,500 older patients with serious non-malignant medical conditions across Finnish university hospitals.
Tampere University HospitalRecruitingNCT07740239 ↗
720

Indiana University Health North Hospital

Carmel · Indiana · United States

1 trial
Zopocianine (OTL78) with near-infrared imaging is tested to improve detection of prostate cancer tissue during surgery.
Clinton BahlerPh 2 / Ph 3NCT07725523 ↗
721

Indiana University School of Medicine

Indianapolis · Indiana · United States

1 trial
Zopocianine (OTL78) with near-infrared imaging is tested to improve detection of prostate cancer tissue during surgery.
Clinton BahlerPh 2 / Ph 3NCT07725523 ↗
722

London Health Sciences Centre, Verspeeten Family Cancer Centre

London · Ontario · Canada

1 trial
Micro-ultrasound guided radiation boost combined with stereotactic body radiation therapy is tested for treating prostate cancer.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT07737457 ↗
723

Sun Yat-sen University Cancer Center

Guangzhou · Guangdong · China

1 trial
SHR-6914 injection safety, tolerability, and efficacy are evaluated in adult patients with prostate cancer.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ph 1NCT07735377 ↗
724

Prince of Wales Hospital, Urology Division

Hong Kong · Hong Kong

1 trial
eMindExCare, an integrated mindfulness and exercise online program, is tested in prostate cancer patients undergoing active treatment.
The University of Hong KongNCT07735273 ↗
725

Ahmadu Bello University Teaching Hospital

Zaria · Kaduna State · Nigeria

1 trial
Prostate cancer risk calculators are validated to improve early detection in high-risk Nigerian men.
Ahmadu Bello UniversityNCT07733440 ↗
726

IRCCS Humanitas Research Hospital

Rozzano · Milan · Italy

1 trial
Advanced CT imaging visualizes the urethra without catheterization to improve radiation safety during prostate cancer treatment planning.
Istituto Clinico HumanitasRecruitingNCT07730203 ↗
727

Banner MD Anderson Cancer Center at Gateway

Gilbert · Arizona · United States

1 trial
Semaglutide weight-loss drug given before prostate surgery examines effects in intermediate-risk prostate cancer patients.
Banner HealthPh 1 (early)NCT07727473 ↗
728

START Los Angeles

Los Angeles · California · United States

1 trial
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1RecruitingNCT07719361 ↗
729

START Midwest

Grand Rapids · Michigan · United States

1 trial
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1RecruitingNCT07719361 ↗
730

START Carolinas

Myrtle Beach · South Carolina · United States

1 trial
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1RecruitingNCT07719361 ↗
731

START Dallas-Fort Worth

Fort Worth · Texas · United States

1 trial
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1RecruitingNCT07719361 ↗
732

NEXT Houston

Houston · Texas · United States

1 trial
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1Opening soonNCT07719361 ↗
733

NEXT Virginia

Fairfax · Virginia · United States

1 trial
FX-111 experimental drug evaluates safety and effectiveness in men with metastatic castration-resistant prostate cancer.
Flare Therapeutics Inc.Ph 1Opening soonNCT07719361 ↗
734

Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Beijing · China

1 trial
Modified surgical technique with urethral suspension improves urinary control recovery after robot-assisted prostate removal.
Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07725653 ↗
735

UMC Ljubljana

Ljubljana · Slovenia

1 trial
Electrical stimulation of nerve bundles during robotic prostate surgery to preserve erectile function in localized prostate cancer patients.
University Medical Centre LjubljanaNCT07724028 ↗
736

University of Bath

Bath · Somerset · United Kingdom

1 trial
Supervised resistance exercise to prevent muscle loss and strengthen immunity in prostate cancer patients receiving hormone therapy.
University of BathNCT07724080 ↗
737

Nanjing Drum Tower Hospital, Affilitated Hospital of Medical School, Nanjing University

Nanjing · Jiangsu · China

1 trial
Rezvilutamide monotherapy as alternative to long-term hormone therapy in high-risk prostate cancer patients after surgery.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPh 2RecruitingNCT07711314 ↗
738

University of Pennsylvania Abramson Cancer Center

Philadelphia · Pennsylvania · United States

1 trial
Fluorthanatrace imaging and blood tests to predict treatment response to PARP inhibitors in metastatic prostate cancer.
Washington University School of MedicinePh 2NCT07723651 ↗
739

Urology Specialists of the Carolinas - University Place

Charlotte · North Carolina · United States

1 trial
Rinzimetostat combined with darolutamide versus standard treatments in metastatic prostate cancer resistant to prior hormone therapy.
ORIC PharmaceuticalsPh 3RecruitingNCT07723248 ↗
740

Summit Urology

Murray · Utah · United States

1 trial
Rinzimetostat combined with darolutamide versus standard treatments in metastatic prostate cancer resistant to prior hormone therapy.
ORIC PharmaceuticalsPh 3RecruitingNCT07723248 ↗
741

Del Sol Research Management, LLC

Tucson · Arizona · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
742

Arizona Urology Specialists

Tucson · Arizona · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
743

Urology Associates of Central California

Fresno · California · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
744

VA Medical Center

San Francisco · California · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
745

Associated Urological Specialists LLC

Chicago Ridge · Illinois · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
746

Advanced Urology Associates

Joliet · Illinois · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
747

Urology of Indiana

Greenwood · Indiana · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
748

First Urology, PSC

Jeffersonville · Indiana · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
749

Maryland Oncology Hematology P A

Silver Spring · Maryland · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
750

MSKCC Basking Ridge

Basking Ridge · New Jersey · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
751

MSKCC Monmouth

Middletown · New Jersey · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
752

MSKCC Bergen

Montvale · New Jersey · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
753

MSKCC Commack

Commack · New York · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
754

MSKCC Westchester

Harrison · New York · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
755

Associated Medical Professionals

Syracuse · New York · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
756

MSKCC Nassau Regional Cancer Center

Uniondale · New York · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
757

TriState Urologic Services PSC Inc. DBA The Urology Group

Cincinnati · Ohio · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
758

Central Ohio Urology Group

Gahanna · Ohio · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
759

Northwest Cancer Specialists PC

Tigard · Oregon · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
760

Centers for Advanced Urology LLC d b a MidLantic Urology

Bala-Cynwyd · Pennsylvania · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
761

The Conrad Pearson Clinic

Germantown · Tennessee · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
762

Texas Oncology P A

Austin · Texas · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
763

Parkland Health and Hospital System

Dallas · Texas · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
764

Texas Oncology P A 3

Dallas · Texas · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
765

Texas Oncology P A 2

Houston · Texas · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
766

Texas Oncology San Antonio Northeast

San Antonio · Texas · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
767

Texas Oncology P A 1

Wichita Falls · Texas · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
768

University of Utah Huntsman Cancer Institute

Salt Lake City · Utah · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
769

Oncology and Hematology Associates of Southwest Virginia, Inc.

Roanoke · Virginia · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
770

Urology Of Virginia, Pllc

Virginia Beach · Virginia · United States

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
771

Macquarie University Hospital

Macquarie University · Australia

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
772

Mater Misericordiae Hospital

South Brisbane · Australia

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
773

Hospital das Clínicas - Universidade Federal de Minas Gerais

Belo Horizonte · Brazil

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
774

Instituto D Or de Pesquisa e Ensino

Salvador · Brazil

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
775

CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia

Santo André · Brazil

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
776

The First Hospital of Jilin University

Changchun · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
777

West China School of Medicine/West China Hospital, Sichuan University

Chengdu · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
778

The First Affiliated Hospital Sun Yat sen University

Guangzhou · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
779

Nanfang Hospital of Southern Medical Hospital

Guangzhou · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
780

Shandong Provincial Hospital

Jinan · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
781

Ningbo First Hospital

Ningbo · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
782

Shengjing Hospital Of China Medical University

Shenyang · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
783

TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology

Wuhan · China

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
784

Hopital Cochin

Paris · France

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
785

Klinikum Augsburg

Augsburg · Germany

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
786

Universitaetsklinikum Carl Gustav Carus TU Dresden

Dresden · Germany

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
787

Klinikum rechts der Isar - der Technischen Universität München

München · Germany

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
788

Universitatsklinikum Wurzburg

Würzburg · Germany

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
789

SCIENTIA Investigacion Clinica SC

Chihuahua City · Mexico

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
790

Medical Care & Research SA de CV

Mérida · Mexico

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
791

Cuidados Oncologicos

Querétaro · Mexico

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
792

Polimed Specjalistyczna Przychodnia Lekarska Wieslaw Grazyna Tupikowski Bednarek Tupikowska S C

Wroclaw · Poland

1 trial
Intermittent apalutamide androgen-deprivation therapy treats metastatic castrate-sensitive prostate cancer.
Janssen Research & Development, LLCPh 3NCT05884398 ↗
793

Mayo Clinic Health System in Albert Lea

Albert Lea · Minnesota · United States

1 trial
Adaptive radiation therapy with two treatments compared to standard stereotactic ablative radiotherapy with five treatments for localized prostate cancer.
Mayo ClinicRecruitingNCT06325046 ↗
794

Mayo Clinic Health System-Mankato

Mankato · Minnesota · United States

1 trial
Adaptive radiation therapy with two treatments compared to standard stereotactic ablative radiotherapy with five treatments for localized prostate cancer.
Mayo ClinicRecruitingNCT06325046 ↗
795

Mayo Clinic Health System-Eau Claire

Eau Claire · Wisconsin · United States

1 trial
Adaptive radiation therapy with two treatments compared to standard stereotactic ablative radiotherapy with five treatments for localized prostate cancer.
Mayo ClinicRecruitingNCT06325046 ↗
796

Mayo Clinic Health System-Franciscan Healthcare

La Crosse · Wisconsin · United States

1 trial
Adaptive radiation therapy with two treatments compared to standard stereotactic ablative radiotherapy with five treatments for localized prostate cancer.
Mayo ClinicRecruitingNCT06325046 ↗
797

City of Hope Medical Center

Duarte · California · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
798

Natera, Inc. (Data or Specimen Analysis Only)

San Carlos · California · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
799

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge · New Jersey · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
800

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown · New Jersey · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
801

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale · New Jersey · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
802

Memorial Sloan Kettering Commack (Limited Protocol Activities)

Commack · New York · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
803

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison · New York · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
804

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale · New York · United States

1 trial
Aerobic exercise study explores whether increased physical activity reduces circulating tumor DNA levels in cancer patients.
City of Hope Medical CenterNCT04589468 ↗
805

Memorial Sloan Kettering Cancer Ctr

New York · New York · United States

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
806

Novartis Investigative Site

Nantes · France

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
807

Novartis Investigative Site

München · Germany

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
808

Novartis Investigative Site

Rostock · Germany

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
809

Novartis Investigative Site

L'Hospitalet de Llobregat · Barcelona · Spain

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
810

Novartis Investigative Site

Sutton · Surrey · United Kingdom

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
811

Novartis Investigative Site

London · United Kingdom

1 trial
Radioligand therapy targeting PSMA, SSTR2, and GRPR evaluated for safety and efficacy in metastatic neuroendocrine prostate cancer.
Novartis PharmaceuticalsPh 1NCT06379217 ↗
812

Rocky Mountain Regional VA Medical Center, Aurora, CO

Aurora · Colorado · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
813

VA Connecticut Healthcare System West Haven Campus, West Haven, CT

West Haven · Connecticut · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
814

North Florida/South Georgia Veterans Health System, Gainesville, FL

Gainesville · Florida · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
815

Orlando VA Medical Center, Orlando, FL

Orlando · Florida · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
816

Atlanta VA Medical and Rehab Center, Decatur, GA

Decatur · Georgia · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
817

Robley Rex VA Medical Center, Louisville, KY

Louisville · Kentucky · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
818

Kansas City VA Medical Center, Kansas City, MO

Kansas City · Missouri · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
819

St. Louis VA Medical Center John Cochran Division, St. Louis, MO

St Louis · Missouri · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
820

Durham VA Medical Center, Durham, NC

Durham · North Carolina · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
821

Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC

Salisbury · North Carolina · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
822

VA Portland Health Care System, Portland, OR

Portland · Oregon · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
823

Ralph H. Johnson VA Medical Center, Charleston, SC

Charleston · South Carolina · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
824

Memphis VA Medical Center, Memphis, TN

Memphis · Tennessee · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
825

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN

Nashville · Tennessee · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
826

Michael E. DeBakey VA Medical Center, Houston, TX

Houston · Texas · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2Opening soonNCT05011383 ↗
827

VA Puget Sound Health Care System Seattle Division, Seattle, WA

Seattle · Washington · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
828

William S. Middleton Memorial Veterans Hospital, Madison, WI

Madison · Wisconsin · United States

1 trial
High-dose testosterone therapy tested in prostate cancer patients with DNA repair deficiencies in ATM, CDK12, or CHEK2 genes.
VA Office of Research and DevelopmentPh 2RecruitingNCT05011383 ↗
829

HonorHealth Research Institute

Phoenix · Arizona · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
830

The Angeles Clinic

Los Angeles · California · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
831

Hoag Memorial Hospital

Newport Beach · California · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
832

California Pacific Medical Center

San Francisco · California · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
833

Sarah Cannon Research Institute

Denver · Colorado · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
834

Orlando Health

Orlando · Florida · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
835

OSF St Francis Medical Center

Peoria · Illinois · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
836

Indiana University

Indianapolis · Indiana · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
837

Dana Faber Cancer Institute

Boston · Massachusetts · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
838

Roswell Park Comprehensive Cancer Center

Buffalo · New York · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
839

Weil Cornell University

New York · New York · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
840

Sarah Cannon Research Institute - Oklahoma University

Oklahoma City · Oklahoma · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
841

University of Pennsylvania

Philadelphia · Pennsylvania · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
842

Sarah Cannon Research Institute - Thomas Jefferson University

Philadelphia · Pennsylvania · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
843

MD Anderson

Houston · Texas · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
844

NEXT Oncology

Irving · Texas · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
845

START Mountain Region

West Valley City · Utah · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
846

NEXT Oncology

Fairfax · Virginia · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
847

Swedish Cancer Institute

Seattle · Washington · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
848

University of Wisconsin

Madison · Wisconsin · United States

1 trial
PARG inhibitor IDE161 evaluated for safety and efficacy alone and combined with pembrolizumab in advanced solid tumors.
IDEAYA BiosciencesPh 1NCT05787587 ↗
849

Faculty of Medicine, Ain Shams University

Cairo · Egypt

1 trial
Hypofractionated simultaneous integrated boost radiotherapy evaluated for safety and efficacy in high-risk and very high-risk localized prostate cancer.
Ain Shams UniversityPh 2RecruitingNCT07693075 ↗
850

Faculty of Medicine - Menoufia University

Shibīn al Kawm · Egypt

1 trial
Hypofractionated simultaneous integrated boost radiotherapy evaluated for safety and efficacy in high-risk and very high-risk localized prostate cancer.
Ain Shams UniversityPh 2RecruitingNCT07693075 ↗
851

Faculty of Medicine - Sohag University

Sohag · Egypt

1 trial
Hypofractionated simultaneous integrated boost radiotherapy evaluated for safety and efficacy in high-risk and very high-risk localized prostate cancer.
Ain Shams UniversityPh 2RecruitingNCT07693075 ↗
852

HCA Florida Kendall Hospital

Miami · Florida · United States

1 trial
AS1986NS fluorescent imaging agent tested for identifying prostate cancer cells in surgical tissue samples.
Antelope Surgical Solutions, IncPh 1 / Ph 2RecruitingNCT06906471 ↗
853

Icahn School of Medicine at Mount Sinai (ISMMS)

New York · New York · United States

1 trial
AS1986NS fluorescent imaging agent tested for identifying prostate cancer cells in surgical tissue samples.
Antelope Surgical Solutions, IncPh 1 / Ph 2Opening soonNCT06906471 ↗
854

Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company

Cleveland · Ohio · United States

1 trial
Real-world study of darolutamide and similar drugs combined with standard therapy for newly diagnosed advanced prostate cancer.
BayerRecruitingNCT07406282 ↗
855

Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Heidelberg

Heidelberg · Baden-Wurttemberg · Germany

1 trial
Adaptive radiation therapy delivered in five weekly treatments for newly diagnosed localized prostate cancer.
University of ZurichOpening soonNCT06834152 ↗
856

Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum LMU

Munich · Bavaria · Germany

1 trial
Adaptive radiation therapy delivered in five weekly treatments for newly diagnosed localized prostate cancer.
University of ZurichOpening soonNCT06834152 ↗
857

University Hospital Zurich, Department of Radio-Oncology

Zurich · Canton of Zurich · Switzerland

1 trial
Adaptive radiation therapy delivered in five weekly treatments for newly diagnosed localized prostate cancer.
University of ZurichRecruitingNCT06834152 ↗
858

University of California Irvine Chao Family Comprehensive Cancer Center

Irvine · California · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2WITHDRAWNNCT04585750 ↗
859

University of San Diego Moores Cancer Center

La Jolla · California · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2Opening soonNCT04585750 ↗
860

UCLA Jonsson Comprehensive Cancer Center

Los Angeles · California · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
861

USC Norris Comprehensive Cancer Center

Los Angeles · California · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
862

Rocky Mountain Cancer Center

Denver · Colorado · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
863

Yale Cancer Center

New Haven · Connecticut · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
864

Medical Oncology Hematology Consultants

Newark · Delaware · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
865

University of Miami - Sylvester Comprehensive Cancer Center

Miami · Florida · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
866

Florida Cancer Specialists South

Port Charlotte · Florida · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
867

University of Nebraska Medical Center Buffet Cancer Center

Omaha · Nebraska · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2Opening soonNCT04585750 ↗
868

Memorial Sloan Kettering

New York · New York · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
869

Duke University

Durham · North Carolina · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
870

The Cleveland Clinic Taussig Cancer Center

Cleveland · Ohio · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
871

University of Oklahoma

Oklahoma City · Oklahoma · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
872

Oregon Health & Science University (OHSU)

Portland · Oregon · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
873

Abramson Cancer Center of the University of Pennsylvania

Philadelphia · Pennsylvania · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
874

WellSpan York Cancer Center

York · Pennsylvania · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
875

New Experimental Therapeutics - NEXT Oncology

Austin · Texas · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
876

Texas Oncology

Bedford · Texas · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
877

UTSW - Moody Outpatient Center - Parkland Health

Dallas · Texas · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2Opening soonNCT04585750 ↗
878

UT Southwest Simmons Cancer Center

Dallas · Texas · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
879

The University of Texas MD Anderson Cancer Center

Houston · Texas · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
880

New Experimental Therapeutics of San Antonio - NEXT Oncology

San Antonio · Texas · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
881

University of Washington, Fred Hutchinson Cancer Center

Seattle · Washington · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
882

University of Wisconsin Carbone Cancer Center

Madison · Wisconsin · United States

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
883

Chris O'Brien Lifehouse Hospital

Camperdown · New South Wales · Australia

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
884

Mater Cancer Care Centre

South Brisbane · Queensland · Australia

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
885

Flinders Medical Center

Bedford Park · South Australia · Australia

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
886

Monash Medical Centre

Clayton · Victoria · Australia

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
887

Linear Clinical Research

Nedlands · Western Australia · Australia

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
888

ICANS - Institut de cancérologie Strasbourg Europe

Strasbourg · Bas-Rhin · France

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
889

Institut Claudius Regaud

Toulouse · Haute-Garonne · France

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
890

EDOG Institut de Cancerologie de l'Ouest

Saint-Herblain · Loire-Atlantique · France

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
891

Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer

Lyon · France

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
892

CHU de Nîmes

Nîmes · France

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
893

Institute Cancer De Lorraine

Vandœuvre-lès-Nancy · France

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
894

Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg

Heidelberg · Baden-Wurttemberg · Germany

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
895

Universitätsklinikum Augsburg

Augsburg · Bavaria · Germany

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
896

Asklepios Klinik Altona

Hamburg · Free and Hanseatic City of Hamburg · Germany

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
897

Universitätsklinikum Frankfurt

Frankfurt am Main · Hesse · Germany

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2WITHDRAWNNCT04585750 ↗
898

Universitätsklinikum Essen

Essen · North Rhine-Westphalia · Germany

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
899

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome · Lazio · Italy

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
900

Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena

Rome · Lazio · Italy

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
901

Fondazione del Piemonte per l'Oncologia (IRCCS)

Candiolo · Torino · Italy

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
902

Humanitas San Pio X

Milan · Italy

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
903

IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale

Naples · Italy

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
904

National University Hospital

Kent Ridge · Singapore

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
905

National Cancer Center of Singapore

Singapore · Singapore

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
906

National Cancer Center

Seoul · South Korea

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
907

Seoul University Hospital

Seoul · South Korea

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
908

Severance Hospital Yonsei University

Seoul · South Korea

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
909

START MADRID_Hospital Universitario Fundacion Jimenez Diaz

Madrid · Madrid · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
910

START MADRID_Hospital Universitario HM Sanchinarro - CIOCC

Madrid · Madrid · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
911

Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON

Barcelona · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
912

NEXT Oncology-Hospital Quironsalud Barcelona

Barcelona · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
913

Hospital Universitario 12 de Octubre

Madrid · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
914

START Rioja

Rioja · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
915

Hospital Clinico Universitario de Valencia

Valencia · Spain

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
916

Sarah Cannon Research Institute UK

London · Middlesex · United Kingdom

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
917

Freeman Hospital

Newcastle upon Tyne · Tyne and Wear · United Kingdom

1 trial
Drug rezatapopt tested for advanced solid tumors with specific TP53 Y220C genetic mutation.
PMV Pharmaceuticals, IncPh 1 / Ph 2RecruitingNCT04585750 ↗
918

University of California Los Angeles, Department of Urology

Los Angeles · California · United States

1 trial
Micro-ultrasound compared to MRI for detecting significant prostate cancer during active surveillance monitoring.
University of AlbertaRecruitingNCT05558241 ↗
919

Kipnes Urology Centre - Kaye Edmonton Clinic

Edmonton · Alberta · Canada

1 trial
Micro-ultrasound compared to MRI for detecting significant prostate cancer during active surveillance monitoring.
University of AlbertaRecruitingNCT05558241 ↗
920

University of British Columbia

Vancouver · Alberta · Canada

1 trial
Micro-ultrasound compared to MRI for detecting significant prostate cancer during active surveillance monitoring.
University of AlbertaRecruitingNCT05558241 ↗
921

CIUSSS du Nord-de-L'Ile-De-Montreal

Montreal · Quebec · Canada

1 trial
Micro-ultrasound compared to MRI for detecting significant prostate cancer during active surveillance monitoring.
University of AlbertaRecruitingNCT05558241 ↗
922

University Hospital Centre Zagreb

Zagreb · Croatia

1 trial
Micro-ultrasound compared to MRI for detecting significant prostate cancer during active surveillance monitoring.
University of AlbertaRecruitingNCT05558241 ↗
923

Humanitas

Milan · Italy

1 trial
Micro-ultrasound compared to MRI for detecting significant prostate cancer during active surveillance monitoring.
University of AlbertaRecruitingNCT05558241 ↗
924

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge · New Jersey · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
925

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown · New Jersey · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
926

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale · New Jersey · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
927

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

Commack · New York · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
928

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison · New York · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
929

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York · New York · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
930

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale · New York · United States

1 trial
Enhanced telehealth delivery of cancer care to reduce in-person visits for patients receiving cancer treatment.
Memorial Sloan Kettering Cancer CenterRecruitingNCT06954337 ↗
931

University of Southern California

Los Angeles · California · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
932

University of California Los Angeles

Los Angeles · California · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
933

University of California Irvine Medical Center Chao Family Comprehensive Cancer Center

Orange · California · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
934

UC Davis Medical Center

Sacramento · California · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
935

AdventHealth Medical Group Urology of Denver

Denver · Colorado · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
936

Stamford Hospital

Stamford · Connecticut · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
937

Urology Specialists LLC

Hialeah · Florida · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
938

Miami Cancer Institute at Baptist Health / Baptist Health Medical Group

Miami · Florida · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
939

University of Chicago

Chicago · Illinois · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
940

Ochsner LSU Health Shreveport - Regional Urology

Shreveport · Louisiana · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
941

Beth Isreal Deaconess Medical Center

Boston · Massachusetts · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
942

Michigan Institute of Urology, PC

Troy · Michigan · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
943

Saint Louis University

St Louis · Missouri · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
944

Urology Cancer Center, PC

Omaha · Nebraska · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
945

Albany Medical College

Albany · New York · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
946

Great Lakes Physician PC d/b/a Western New York Urology Associates

Cheektowaga · New York · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
947

Memorial Sloan-Kettering Cancer Center

New York · New York · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
948

Weill Cornell Medical College

New York · New York · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
949

SUNY Upstate Medical University

Syracuse · New York · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
950

University of North Carolina

Chapel Hill · North Carolina · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
951

Duke University School of Medicine

Durham · North Carolina · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
952

Medication Management LLC

Greensboro · North Carolina · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
953

Carolina Urology Partners, PLLC

Huntersville · North Carolina · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
954

Cleveland VA Medical Center

Cleveland · Ohio · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
955

Oklahoma City VAMC

Oklahoma City · Oklahoma · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
956

Omega Medical Research

Warwick · Rhode Island · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
957

Ralph H. Johnson Veterans Affairs Medical Center

Charleston · South Carolina · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
958

Greenville Health

Greenville · South Carolina · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
959

Vanderbilt University Medical Center

Nashville · Tennessee · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
960

VA North Texas Health Care System

Dallas · Texas · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
961

Virginia Urology

Richmond · Virginia · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
962

CAMC Memorial Hospital, Charleston Area Medical Center Physicians

Charleston · West Virginia · United States

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
963

Hospital Aleman

Caba · Argentina

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
964

Hospital Italiano de Buenos Aires

Ciudad Autonoma de · Argentina

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
965

Centro Urologico Profesor Bengio

Córdoba · Argentina

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
966

Uroclinica

Mendoza · Argentina

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
967

Clinica Mayo de UMCB

San Miguel de Tucumán · Argentina

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
968

Eastern Health - Box Hill Hospital

Box Hill · Australia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
969

Austin Health

Heidelberg · Australia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
970

Australian Urology Associates Pty Ltd

Malvern · Australia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
971

Royal Melbourne Hospital

Parkville · Australia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
972

Northern Cancer Institute

St Leonards · Australia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
973

Westmead Hospital

Westmead · Australia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
974

Associacao Umane

São Paulo · Brazil

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
975

Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo

São Paulo · Brazil

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
976

Instituto Do Cancer Brasil

Três Lagoas · Brazil

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
977

Prostate Cancer Centre

Calgary · Alberta · Canada

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
978

Vancouver Prostate Centre, Gordon and Leslie Diamond Health Care Centre

Vancouver · British Columbia · Canada

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
979

London Health Sciences Center

London · Ontario · Canada

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
980

CHUM - Centre hospitalier universitaire de Montreal

Montreal · Quebec · Canada

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
981

Vseobecna fakultni nemocnice v Praze

Prague · Czechia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
982

Thomayerova nemocnice

Prague · Czechia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
983

CHU d'Angers

Angers · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
984

CHRU Besancon Hopital Jean Minjoz

Besançon · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
985

Hopital Pellegrin CHU Bordeaux

Bordeaux · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
986

APHP - Hopital Henri Mondor

Créteil · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
987

Hopital Edouard Herriot - CHU Lyon

Lyon · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
988

CHU de Nantes hotel Dieu

Nantes · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
989

Institut Mutualiste Montsouris

Paris · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
990

Clinique de la Croix du Sud

Quint-Fonsegrives · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
991

CHU de Toulouse - Hôpital Rangueil

Toulouse · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
992

CHRU Tours Hopital Bretonneau

Tours · France

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
993

Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie

Braunschweig · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
994

Praxis Dr. med. Ralf Eckert

Eisleben Lutherstadt · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
995

Universitatsklinikum Essen

Essen · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
996

Universitatsklinikum Frankfurt

Frankfurt am Main · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
997

Prostata zentrum Nordwest

Gronau · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
998

Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie

Hamburg · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
999

Universitätsklinikum des Saarlandes

Homburg/Saar · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1000

Klinikum St. Elisabeth Straubing GmbH

Straubing · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1001

Kliniken Nordoberpfalz, Klinik für Urologie

Weiden/Opf · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1002

Praxisgemeinschaft f. Onkologie u. Urologie - Germany

Wilhelmshaven · Germany

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1003

Tel Aviv University Sackler School of Medicine - Meir Medical Center (MMC)

Kfar Saba · Israel

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1004

The Chaim Sheba Medical Center

Ramat Gan · Israel

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1005

Tel Aviv Sourasky Medical Center

Tel Aviv · Israel

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1006

Policlinico Abano Terme

Abano Terme · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1007

Generale Regionale F. Miulli

Acquaviva delle Fonti · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1008

Ospedale di Bassano del Grappa

Bassano del Grappa · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1009

ASST Spedali Civili Brescia

Brescia · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1010

ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti

Chieti · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1011

Azienda Ospedaliero Universitaria Careggi

Florence · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1012

San Raffaele Turro - Istituto di Ricovero e Cura a Carattere Scientifico

Milan · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1013

Clinica di Urologia Policlinico di Modena - Universita di Modena e reggio Emilia

Modena · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1014

Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara

Novara · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1015

Universita degli Studi di Torino - Azienda Ospedaliero-Universitaria San Luigi Gonzaga

Orbassano · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1016

Universita Campus Bio-Medico di Roma

Roma · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1017

Istituto Nazionale Tumori Regina Elena

Roma · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1018

Azienda Ospedaliera Sant Andrea

Roma · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1019

Ospedale Molinette, AO Città della Salute e della Scienza di

Torino · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1020

UOC di Urologia AOU Integrata di Verona - Polo Chirurgico Confortini - Ospedale Borgo Trento

Verona · Italy

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1021

Akita University Hospital

Akita · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1022

Chiba University Hospital

Chiba · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1023

Chiba Cancer Center

Chūōku · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1024

Hakodate Goryoukaku Hospital

Hakodate · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1025

Hirosaki University Hospital

Hirosaki · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1026

Kobe City Medical Center General Hospital

Kobe · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1027

Dokkyo Medical University Saitama Medical Center

Koshigaya · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1028

Kurume University Hospital

Kurume · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1029

Kitasato University Hospital

Minamiku · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1030

University of Miyazaki Hospital

Miyazaki · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1031

Nagano Municipal Hospital

Nagano · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1032

Kindai University Hospital

Sakai · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1033

Hokkaido University Hospital

Sapporo · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1034

Iwate Medical University Hospital

Shiwa-gun · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1035

Nippon Medical School Hospital

Tokyo · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1036

Juntendo University Hospital

Tokyo · Japan

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1037

Catharinaziekenhuis

Eindhoven · Netherlands

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1038

Canisius-Wilhelmina Ziekenhuis

Nijmegen · Netherlands

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1039

Samodzielny Publiczny Wielospecjalistyczny Zaklad Opieki Zdrowotnej Mswia W Bydgoszczy

Bydgoszcz · Poland

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1040

Pratia MCM Krakow

Krakow · Poland

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1041

City Clinic Sp. z o.o.

Warsaw · Poland

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1042

Dolnoslaskie Centrum Onkologii, Oddzial Chirurgii Onkologicznej II - Urologia

Wroclaw · Poland

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1043

Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine

Chelyabinsk · Russia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1044

Moscow City Oncology Hospital № 62

Moscow · Russia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1045

Hertzen Oncology Research Institute

Moscow · Russia

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1046

Seoul National University Bundang Hospital

Gyeonggi-do · South Korea

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1047

Asan Medical Center 1

Seoul · South Korea

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1048

Hosp Univ A Coruna

A Coruña · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1049

Hosp. Puerta Del Mar

Cadiz · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1050

Hosp. Gral. Univ. de Castellon

Castellon · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1051

Hosp. Univ. La Paz

Madrid · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1052

Fund. Hosp. de Manacor

Manacor · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1053

Hosp. Virgen Del Rocio

Seville · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1054

Inst. Valenciano de Oncologia

Valencia · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1055

Hosp. Clinico Univ. de Valencia

Valencia · Spain

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1056

Southmead Hospital

Bristol · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1057

University Hospital of Wales

Cardiff · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1058

Ninewells Hospital

Dundee · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1059

The Royal Marsden NHS Trust

London · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1060

University College London

London · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1061

Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital

Preston · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1062

Royal Marsden Hospital

Sutton · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1063

Mid Yorkshire NHS Trust

Wakefield · United Kingdom

1 trial
Apalutamide plus hormone therapy before and after surgery to improve outcomes in high-risk localized prostate cancer.
Janssen Research & Development, LLCPh 3NCT03767244 ↗
1064

UM Sylvester Comprehensive Cancer Center at Aventura

Aventura · Florida · United States

1 trial
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
1065

University of Kansas Hospital-Indian Creek Campus

Overland Park · Kansas · United States

1 trial
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
1066

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison · Wisconsin · United States

1 trial
M1774 drug to treat refractory prostate cancer harboring SPOP gene mutations.
National Cancer Institute (NCI)Ph 2NCT05828082 ↗
1067

Institut de Cancérologie de l'Ouest Paul Papin

Angers · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1068

Centre Francois Baclesse

Caen · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1069

Centre hospitalier Métropole Savoie

Chambéry · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1070

Clinique Léonard de Vinci

Chambray-lès-Tours · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1071

CHU Henri Mondor

Créteil · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1072

Centre Léon Bérard

Lyon · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1073

Hopital La Timone

Marseille · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1074

Centre de Cancérologie du Grand Montpellier

Montpellier · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1075

Centre Val D'Aurelle

Montpellier · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1076

Centre Azureen de Cancerologie

Mougins · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1077

Chr Orleans

Orléans · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1078

Hôpital Saint Louis

Paris · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1079

Centre Hospitalier Lyon Sud

Pierre-Bénite · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1080

Centre CARIO - HPCA

Plérin · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1081

Hôpital Jean Bernard - CHU de Poitiers

Poitiers · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1082

Centre Eugène Marquis

Rennes · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1083

Centre Henri Becquerel

Rouen · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1084

Centre Rene Gauducheau

Saint-Herblain · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1085

Institut de Cancérologie LUCIEN NEUWIRTH

Saint-Priest-en-Jarez · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1086

Centre Paul Strauss

Strasbourg · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1087

Ch Bretonneau

Tours · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1088

Centre Alexis Vautrin

Vandœuvre-lès-Nancy · France

1 trial
Comparing radiation doses with hormone therapy in treating locally advanced prostate cancer.
UNICANCERNCT00967863 ↗
1089

Northwestern Memorial Hospital

Chicago · Illinois · United States

1 trial
TheraSphere radioactive device safety testing across different doses in localized prostate cancer patients.
Boston Scientific CorporationNCT06192758 ↗
1090

Clinique Pasteur Lanroze - Brest

Brest · France

1 trial
Darolutamide drug plus high-dose focused radiation therapy for localized prostate cancer with high relapse risk.
UNICANCERPh 3RecruitingNCT06625970 ↗
1091

Groupe Hospitalier Paris Saint-Joseph

Paris · France

1 trial
Darolutamide drug plus high-dose focused radiation therapy for localized prostate cancer with high relapse risk.
UNICANCERPh 3RecruitingNCT06625970 ↗
1092

CHU Saint-Etienne

Saint-Etienne · France

1 trial
Darolutamide drug plus high-dose focused radiation therapy for localized prostate cancer with high relapse risk.
UNICANCERPh 3RecruitingNCT06625970 ↗
1093

Gustave Roussy, Cancer Campus, Grand Paris

Villejuif · France

1 trial
Darolutamide drug plus high-dose focused radiation therapy for localized prostate cancer with high relapse risk.
UNICANCERPh 3RecruitingNCT06625970 ↗
1094

CHU Martinique

Fort-de-France · Martinique

1 trial
Darolutamide drug plus high-dose focused radiation therapy for localized prostate cancer with high relapse risk.
UNICANCERPh 3RecruitingNCT06625970 ↗
1095

University of Colorado Anschutz Medical Campus

Aurora · Colorado · United States

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1096

University Of Minnesota

Minneapolis · Minnesota · United States

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1097

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

New York · New York · United States

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1098

Sidney Kimmel Cancer Center - Jefferson Health

Philadelphia · Pennsylvania · United States

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1099

South Texas Accelerated Research Therapeutics, LLC (START)

San Antonio · Texas · United States

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1100

Swedish Medical Center

Seattle · Washington · United States

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1101

Greenslopes Private Hospital

Greenslopes · Australia

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1102

The Cancer Institute Hospital of JFCR

Tokyo · Japan

1 trial
Two experimental drugs combined, with or without apalutamide, for advanced prostate cancer.
Janssen Research & Development, LLCPh 1RecruitingNCT06095089 ↗
1103

Mayo Clinic Arizona

Phoenix · Arizona · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1104

Urological Associates of Southern Arizona, P.C.

Tucson · Arizona · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1105

Kaiser Permanente

Riverside · California · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1106

San Bernardino Urological Associates

San Bernardino · California · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1107

The Urology Center of Colorado

Denver · Colorado · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1108

VA Connecticut Healthcare

West Haven · Connecticut · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1109

University of Florida Health Jacksonville

Jacksonville · Florida · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1110

Veterans Affairs Medical Ctr

Hines · Illinois · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1111

Fort Wayne Medical Oncology and Hematology

Fort Wayne · Indiana · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1112

First Urology

Jeffersonville · Indiana · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1113

Norton Healthcare

Louisville · Kentucky · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1114

Ochsner Clinic Foundation

New Orleans · Louisiana · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1115

Rcca Md, Llc

Bethesda · Maryland · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1116

Massachusetts General

Boston · Massachusetts · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1117

Kansas City Veterans Affairs Medical Center

Kansas City · Missouri · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1118

Adult Pediatric Urology & Urogynecology, P.C

Omaha · Nebraska · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1119

Delaware Valley Urology, LLC

Mount Laurel · New Jersey · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1120

New York Oncology Hematology

Albany · New York · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1121

Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg

New York · New York · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1122

Upstate Cancer Center

Syracuse · New York · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1123

Lancaster Urology

Lancaster · Pennsylvania · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1124

Salem VA Medical Center

Salem · Virginia · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1125

NorthWest Medical Specialties, PLLC

Tacoma · Washington · United States

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1126

Hospital Aleman

Buenos Aires · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1127

Centro Oncológico Korben

Buenos Aires · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1128

CEMIC Saavedra

Buenos Aires · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1129

Centro de Urologia (CDU)

Ciudad Automoma Buenos Aires · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1130

Hospital Privado Centro Medico de Cordoba

Córdoba · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1131

Instituto de Investigaciones Clinicas Mar del Plata

Mar del Plata · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1132

Hospital Privado de Comunidad

Mar del Plata · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1133

Centro de Investigacion Pergamino SA

Pergamino · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1134

Sanatorio Britanico de Rosario

Rosario · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1135

Sanatorio Parque

Rosario · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1136

ARS Médica

San Salvador de Jujuy · Argentina

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1137

Royal Adelaide Hospital

Adelaide · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1138

Pindara Private Hospital

Benowa · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1139

Sunshine Coast University Hospital

Birtinya · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1140

Princess Alexandra Hospital

Brisbane · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1141

Royal Hobart Hospital

Hobart · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1142

Macquarie University

Macquarie University · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1143

Eye Surgery Associates

Malvern · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1144

Hollywood Private Hospital

Nedlands · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1145

Prince Of Wales Hospital

Randwick · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1146

Wollongong Private Hospital

Wollongong · Australia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1147

OLV Ziekenhuis Aalst

Aalst · Belgium

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1148

ZAS Augustinus

Antwerp · Belgium

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1149

Grand Hopital de Charleroi, site Notre Dame

Charleroi · Belgium

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1150

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

Liège · Belgium

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1151

ZNA Jan Palfijn

Merksem · Belgium

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1152

PERSONAL Oncologia de Precisao e Personalizada

Belo Horizonte · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1153

Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia

Brasília · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1154

CIONC Centro Integrado de Oncologia de Curitiba

Curitiba · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1155

Pronutrir

Fortaleza · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1156

Fundacao Sao Francisco Xavier

Ipatinga · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1157

Medradius Clinica de Medicina Nuclear e Radiologia de Maceio Ltda.

Maceió · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1158

Hospital Ernesto Dornelles

Porto Alegre · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1159

Oncoclinicas Rio de Janeiro S A

Rio de Janeiro · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1160

Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

Rio de Janeiro · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1161

Hospital Santa Isabel

Salvador · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1162

Fundacao do ABC Centro Universitario FMABC

Santo André · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1163

Irmandade Santa Casa de Misericordia de Sao Paulo

São Paulo · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1164

Instituto de Ensino e Pesquisa São Lucas

São Paulo · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1165

Hospital Alemao Oswaldo Cruz

São Paulo · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1166

Núcleo de Pesquisa São Camilo

São Paulo · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1167

Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE

São Paulo · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1168

Instituto D Or de Pesquisa e Ensino IDOR

São Paulo · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1169

IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado

Sorocaba · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1170

Instituto do Cancer De Tres Lagoas

Três Lagoas · Brazil

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1171

MHAT Deva Maria

Burgas · Bulgaria

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1172

UMHAT 'Dr. Georgi Stranski', EAD

Pleven · Bulgaria

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1173

Complex Oncology Center - Plovdiv EOOD

Plovdiv · Bulgaria

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1174

Specialized Hospital for Active Treatment in Oncology EAD

Sofia · Bulgaria

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1175

SHATOD 'Dr. Marko Antonov Markov'

Varna · Bulgaria

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1176

Comprehensive Cancer Center

Vratsa · Bulgaria

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1177

British Columbia Cancer Agency BCCA Vancouver Centre

Vancouver · British Columbia · Canada

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1178

British Columbia Cancer Agency Vancouver Island Centre

Victoria · British Columbia · Canada

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1179

McMaster Institute of Urology

Hamilton · Ontario · Canada

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1180

Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre)

Kingston · Ontario · Canada

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1181

Centre de Recherche du CHUM

Montreal · Quebec · Canada

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1182

Saskatoon Cancer Centre

Saskatoon · Saskatchewan · Canada

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1183

Cancer Hospital Chinese Academy of Medical Sciences

Beijing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1184

Beijing Friendship Hospital

Beijing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1185

Beijing Cancer Hospital of Peking University

Beijing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1186

Peking University Third Hospital

Beijing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1187

Beijing Hospital

Beijing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1188

Sichuan Provincial Peoples Hospital

Chengdu · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1189

Southwest Hospital, The Third Military Medical University

Chongqing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1190

Fujian Medical University Union Hospital

Fuzhou · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1191

Sun Yat-Sen Memorial Hospital Sun Yat-sen University

Guangzhou · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1192

Guangzhou First Municipal People's Hospital

Guangzhou · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1193

Jiangsu Cancer Hospital

Nanjing · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1194

Drug clinical trial ethics committee of Ningbo First Hospital

Ningbo · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1195

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1196

Huashan Hospital Fudan University

Shanghai · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1197

ShangHai Huadong Hospital

Shanghai · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1198

The Fifth People's Hospital of Shanghai, Fudan University

Shanghai · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1199

The First Affiliated Hospital of Soochow University

Suzhou · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1200

Tianjin Medical University Cancer Hospital

Tianjin · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1201

The Central Hospital of Wuhan

Wuhan · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1202

Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology

Wuhan · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1203

Wuxi People s Hospital

Wuxi · China

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1204

Multiscan s.r.o.

Pardubice · Czechia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1205

Urologicka klinika 1 LF UK a VFN

Prague · Czechia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1206

Thomayerova nemocnice, Onkologicka klinika

Prague · Czechia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1207

Uherskohradistska nemocnice a.s.

Uherské Hradiště · Czechia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1208

CHRU De Besancon

Besançon · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1209

Institut Regional du Cancer de Montpellier Val d'Aurelle

Montpellier · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1210

Polyclinique de Gentilly

Nancy · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1211

Centre Antoine Lacassagne

Nice · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1212

Hopital Europeen Georges-Pompidou

Paris · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1213

Institut de Cancerologie de l Ouest ICO

Saint-Herblain · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1214

Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

Strasbourg · France

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1215

Städtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer

Braunschweig · Germany

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1216

Universitätsklinikum des Saarlandes

Homburg · Germany

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1217

Universitätsklinikum Otto-von-Guericke-Universität Magdeburg

Magdeburg · Germany

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1218

Studienpraxis Urologie Drs. Feyerabend

Nürtingen · Germany

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1219

Semmelweis Egyetem, Urológia Klinika

Budapest · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1220

Országos Onkológiai Intézet, C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály

Budapest · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1221

Debreceni Egyetem Klinikai Kozpont

Debrecen · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1222

Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz

Gyula · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1223

Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz

Nyíregyháza · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1224

Uro-Clin Kft.

Pécs · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1225

Szegedi Tudomanyegyetem

Szeged · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1226

Szegedi Tudomanyegyetem 1

Szeged · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1227

Markusovszky Egyetemi Oktatokorhaz

Szombathely · Hungary

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1228

Sheba Medical Center Tel Hashomer

Ramat Gan · Israel

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1229

AUSL Romagna - Ospedale di Faenza

Faenza · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1230

Oncologia Medica A - Ist Naz Tumori G Pascale

Naples · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1231

Istituto Oncologico Veneto Iov Irccs Padova

Padova · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1232

Oncologia Medica - Azienda Ospedaliero Universitaria Di Parma

Parma · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1233

Ospedale S. Maria Della Misericordia Centro Operativo Studi Clinici SC Oncologia Medica

Perugia · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1234

Azienda Ospedaliero Universitaria Pisana

Pisa · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1235

Campus Bio Medico di Roma

Roma · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1236

Azienda Ospedaliera S. Maria Terni

Terni · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1237

A.O.U. Città della Salute e della Scienza

Torino · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1238

Ospedale Santa Chiara Trento

Trento · Italy

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1239

Hospital Pulau Pinang

George Town · Malaysia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1240

Hospital Sultan Ismail

Johor Bahru · Malaysia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1241

Hospital Likas

Kota Kinabalu · Malaysia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1242

Hospital Kuala Lumpur

Kuala Lumpur · Malaysia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1243

University Malaya Medical Centre

Kuala Lumpur · Malaysia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1244

Sarawak General Hospital

Kuching · Malaysia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1245

iBiomed Research Unit

Aguascalientes · Mexico

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1246

Mexico Centre for Clinical Research, S.A. de C.V.

Mexico City · Mexico

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1247

Avix Investigacion Clinica S C

Monterrey · Mexico

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1248

Consultorio Privado

Zapopan · Mexico

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1249

Universitair Medisch Centrum Groningen

Groningen · Netherlands

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1250

MC Haaglanden Lok Antoniushove - Afd.Interne - INT

Leidschendam · Netherlands

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1251

Canisius-Wilhelminaziekenhuis

Nijmegen · Netherlands

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1252

Zuyderland Medical Center

Sittard-Geleen · Netherlands

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1253

Uniwersyteckie Centrum Kliniczne

Gdansk · Poland

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1254

Szpitale Pomorskie Sp z o o

Gdynia · Poland

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1255

Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi

Lodz · Poland

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1256

Urologica Praktyka Lekarska Adam Marcheluk

Siedlce · Poland

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1257

Pomorski Uniwersytet Medyczny w Szczecinie

Szczecin · Poland

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1258

Dolnoslaskie Centrum Onkologii

Wroclaw · Poland

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1259

Hospitais da universidade de Coimbra

Coimbra · Portugal

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1260

Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE

Coimbra · Portugal

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1261

Champalimaud Foundation Champalimaud Centre

Lisbon · Portugal

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1262

Centro Hospitalar Lisboa Norte EPE Hosp. Santa Maria

Lisbon · Portugal

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1263

H. Santo António - Centro Hospitalar do Porto

Porto · Portugal

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1264

VA Caribbean Healthcare System

San Juan · Puerto Rico

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1265

Ivanovo Regional Oncology Dispensary

Ivanovo · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1266

GUZ Kursk Regional Oncology Dispensary

Kursk · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1267

Russian Scientific Center of Roentgenoradiology

Moscow · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1268

Moscow City Clinical Hospital # 62

Moscow · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1269

Clinical Diagnostic Centre of Nizhny Novgorod Region

Nizhny Novgorod · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1270

LLC Novaya Clinica

Pyatigorsk · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1271

Pyatigorsk Interdistrict Oncology Dispensary

Pyatigorsk · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1272

Leningrad Regional Oncology Dispensary

Saint Petersburg · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1273

Private Medical Institution Euromedservice

Saint Petersburg · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1274

Russian Scientific Center of Radiology and Surgical Technologies

Saint Petersburg · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1275

Republican Oncology Dispensary

Saransk · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1276

Oncologic Dispensary No.2

Sochi · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1277

Tambov Regional Oncology Clinical Dispansary

Tambov · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1278

Tomsk Cancer Research Institute

Tomsk · Russia

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1279

Clinresco Centres Pty Ltd

Johannesburg · South Africa

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1280

Clinical Research Unit

Pretoria · South Africa

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1281

Pusan National University Hospital

Busan · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1282

Kyungpook National University Chilgok Hospital

Daegu · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1283

Keimyung University Dongsan Hospital

Daegu · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1284

National Cancer Center

Gyeonggi-do · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1285

Ajou University Hospital

Gyeonggi-do · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1286

Seoul National University Bundang Hospital

Seongnam-si · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1287

Seoul National University Hospital

Seoul · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1288

Gangnam Severance Hospital, Yonsei University Health System

Seoul · South Korea

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1289

Hospital Juan Canalejo

A Coruña · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1290

Hosp. Del Mar

Barcelona · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1291

Hosp. de La Santa Creu I Sant Pau

Barcelona · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1292

Hosp Clinic de Barcelona

Barcelona · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1293

Hosp. Clinico San Carlos

Madrid · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1294

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1295

Corporacio Sanitari Parc Tauli

Sabadell · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1296

Hosp. Univ. I Politecni La Fe

Valencia · Spain

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1297

Sodersjukhuset

Stockholm · Sweden

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1298

Karolinska Universitetssjukhuset Solna

Stockholm · Sweden

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1299

Akademiska Sjukhuset

Uppsala · Sweden

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1300

Chang Gung Memorial Hospital

Taoyuan · Taiwan

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1301

Cukurova University, Faculty of Medicine

Adana · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1302

Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital

Ankara · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1303

Ankara Bilkent Sehir Hastanesi

Ankara · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1304

Akdeniz University Medical Faculty

Antalya · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1305

Trakya University Medical Faculty

Edirne · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1306

Istanbul University Cerrahpasa Medical Faculty

Istanbul · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1307

Bakirkoy Training and Research Hospital

Istanbul · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1308

Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi

Istanbul · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1309

IEU Medical Point Hospital

Izmir · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1310

Kocaeli University Medical Faculty

Kocaeli · Turkey (Türkiye)

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1311

CNE Clinical Center of Oncology Hematology Transplantology and Palliative Care of the Cherkasy RC

Cherkasy · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1312

Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc

Dnipo · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1313

Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council

Dnipro · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1314

Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4

Dnipro · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1315

Ivano-Frankivsk Regional Clinical Hospital

Ivano-Frankivsk · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1316

Municipal non-profit enterprise 'Regional Center of Oncology'

Khakhiv · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1317

Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval

Kharkiv · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1318

State Nonprofit Enterprise National Cancer Institute

Kyiv · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1319

State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center

Kyiv · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1320

University Hospital of SNA Danylo Halytsky LMNU

Lviv · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1321

ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council'

Poltava · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1322

Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal

Uzhhorod · Ukraine

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1323

Royal Blackburn Hospital

Blackburn · United Kingdom

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1324

Royal Lancaster Infirmary

Lancaster · United Kingdom

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1325

UCL Cancer Institute

London · United Kingdom

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1326

Torbay Hospital-Devon

Torquay · United Kingdom

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1327

Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital

Truro · United Kingdom

1 trial
Niraparib added to abiraterone acetate and prednisone versus abiraterone acetate and prednisone alone for metastatic prostate cancer.
Janssen Research & Development, LLCPh 3NCT03748641 ↗
1328

Site US10052

Anchorage · Alaska · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1329

Site US10011

Tucson · Arizona · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1330

Site US10040

Los Angeles · California · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1331

Site US10009

Los Angeles · California · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1332

Site US10067

Orange · California · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT02960022 ↗
1333

Site US10008

San Bernardino · California · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1334

Site US10042

San Diego · California · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1335

Site US10028

Stanford · California · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1336

Site US10001

Aurora · Colorado · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1337

Site US10017

Denver · Colorado · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1338

Site US10050

Washington D.C. · District of Columbia · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1339

Site US10049

Daytona Beach · Florida · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1340

Site US10048

Jacksonville · Florida · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2WITHDRAWNNCT02960022 ↗
1341

Site US10002

Chicago · Illinois · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1342

Springfield Clinic, LLP

Springfield · Illinois · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1343

Site US10007

Jeffersonville · Indiana · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1344

Site US10066

Lenexa · Kansas · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1345

Site US10029

Towson · Maryland · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1346

Site US10032

St Louis · Missouri · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1347

Nebraska Medical Hospital

Omaha · Nebraska · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1348

Site US10023

Omaha · Nebraska · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1349

Site US10004

Hackensack · New Jersey · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1350

Site US10024

Garden City · New York · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1351

Site US10055

New York · New York · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1352

Site US10059

New York · New York · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1353

Hudson Valley Urology, PC

Poughkeepsie · New York · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1354

Site US10053

Syracuse · New York · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1355

Site US10030

Chapel Hill · North Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1356

Site US10062

Charlotte · North Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1357

Site US10020

Concord · North Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2WITHDRAWNNCT02960022 ↗
1358

Site US10031

Greensboro · North Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2TERMINATEDNCT02960022 ↗
1359

Eastern Urological Associates

Greenville · North Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1360

Site US10046

Winston-Salem · North Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1361

Site US10035

Cincinnati · Ohio · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1362

Site US10022

Springfield · Oregon · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1363

Site US10027

Lancaster · Pennsylvania · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1364

Site US10005

Pittsburgh · Pennsylvania · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1365

Site US10018

Charleston · South Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1366

Site US10003

Myrtle Beach · South Carolina · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2WITHDRAWNNCT02960022 ↗
1367

Site US10041

Nashville · Tennessee · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1368

Site US10010

Dallas · Texas · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1369

Site US10034

Houston · Texas · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1370

Site US10043

Houston · Texas · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1371

Site US10014

Norfolk · Virginia · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1372

Site US10015

Virginia Beach · Virginia · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1373

Site US10038

Seattle · Washington · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1374

Site US10021

Madison · Wisconsin · United States

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1375

Site AR54005

Buenos Aires · Buenos Aires F.D. · Argentina

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1376

Site AR54007

Rosario · Santa Fe Province · Argentina

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1377

Site AR54008

Buenos Aires · Argentina

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1378

Site AR54003

Cordorba · Argentina

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1379

Site AR54006

San Miguel de Tucumán · Argentina

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1380

Site AR54002

San Miguel de Tucumán · Argentina

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1381

Site AU61014

Albury · New South Wales · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1382

Site AU61001

Tweed Heads · New South Wales · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1383

Site AU61012

Wahroonga · New South Wales · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1384

Site AU61017

Wahroonga · New South Wales · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1385

Site AU61006

Ashford · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1386

Site AU61019

Ballarat · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1387

Site AU61007

East Bentleigh · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1388

Site AU61009

Malvern · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1389

Site AU61021

Parkville · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1390

Site AU61008

South Brisbane · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1391

Site AU61016

St Albans · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1392

Site AU61004

Westmead · Australia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1393

Site AT43001

Vienna · Austria

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1394

Site BE32002

Kortrijk · West-Vlaanderen · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1395

Site BE32009

Anderlecht · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1396

Site BE32004

Brussels · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1397

Site BE32005

Ghent · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1398

Site BE32011

Ghent · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1399

Site BE32007

Hasselt · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1400

Site BE32008

Leuven · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1401

Site BE32001

Liège · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1402

Site BE32003

Turnhout · Belgium

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1403

Site BR55007

Porto Alegre · Rio Grande do Sul · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1404

Site BR55009

Bahia · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1405

Site BR55008

Campinas · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1406

Site BR55004

Ijuí · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT02960022 ↗
1407

Site BR55011

Jaú · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1408

Site BR55002

Rio Grande · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1409

Site BR55010

Santo André · Brazil

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1410

Site CA15003

Kingston · Ontario · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1411

Site CA15021

Toronto · Ontario · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1412

Site CA15001

Granby · Quebec · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2TERMINATEDNCT02960022 ↗
1413

Site CA15019

Abbotsford British Columbia · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1414

Site CA15020

Greenville · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1415

Site CA15011

Montreal · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1416

Site CA15017

Oakville · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1417

Site CA15022

Québec · Canada

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1418

Site CL56007

Santiago · RM · Chile

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1419

Site CL56005

Santiago · RM · Chile

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1420

Site CL56006

Viña del Mar · Valparaiso · Chile

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1421

Site CL56004

IX Region · Chile

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1422

Site CL56002

Santiago · Chile

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1423

Site CL56001

Viña del Mar · Chile

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1424

Site CN86003

Hubei · China

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1425

Site CN86010

Hunan · China

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1426

Site CN86005

Nanjing · China

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1427

Site CZ42004

Olomouc · Czechia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1428

Site CZ42002

Olomouc · Czechia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1429

Site CZ42001

Prague · Czechia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1430

Site CZ42003

Prague · Czechia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1431

Site DK45002

Aalborg · North Denmark · Denmark

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1432

Site DK45003

Aarhus · Denmark

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1433

Site DK45001

Copenhagen · Denmark

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1434

Site DK45004

Herlev · Denmark

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1435

Site DK45006

Vejle · Denmark

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1436

Site FL35802

Tampere · Finland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1437

Site FL35805

Turku · Finland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1438

Site FR33021

Bordeaux · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1439

Site FR33008

La Roche-sur-Yon · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1440

Site FR33010

Lille · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1441

Site FR33002

Lyon · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1442

Site FR33020

Montpellier · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1443

Site FR33006

Nîmes · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1444

Site FR33003

Paris · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1445

Site FR33017

Paris · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1446

Site FR33001

Saint-Herblain · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1447

Site FR33019

Strasbourg · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1448

Site FR33022

Strasbourg · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1449

Site FR33004

Villejuif · France

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1450

Site GE99501

Tbilisi · Georgia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1451

Site DE49007

Waldshut-Tiengen · Baden-Wurttemberg · Germany

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1452

Site DE49006

Mannheim · DE · Germany

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1453

Site DE49001

Duisburg · North Rhine-Westphalia · Germany

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1454

Site DE49010

Bonn · Germany

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1455

Site DE49003

Hamburg · Germany

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1456

Site DE49013

Hamburg · Germany

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1457

Site HK85202

Hong Kong · Hong Kong

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1458

Site IL97206

Haifa · Israel

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT02960022 ↗
1459

Site IL97205

Jerusalem · Israel

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1460

Site IL97202

Peth Tikva · Israel

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1461

Site IL97204

Ramat Gan · Israel

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1462

Site IL97203

Tzrifin Beer Yakov · Israel

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1463

Site IT39008

Faenza (RA) · Emilia-Romagna · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1464

Site IT39001

Arezzo · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1465

Site IT39011

Candiolo · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1466

Site IT39004

Cremona · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1467

Site IT39002

Forlì · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1468

Site IT39009

Toscana · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1469

Site IT39006

Trento · Italy

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1470

Toho University Sakura Medical Center

Sakura-shi · Chiba · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1471

Kyushu University Hospital

Higashiku · Fukuoka · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1472

Gunma University Hospital

Maebashi · Gunma · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1473

Kagawa University Hospital

Kida-gun · Kagawa-ken · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1474

Kindai University Hospital

Sayama · Osaka · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1475

The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Koutou-ku · Tokyo · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1476

Chiba cancer center

Chiba · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1477

Niigata University Medical and Dental Hospital

Niigata · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1478

Osaka Metropolitan University Hospital

Osaka · Japan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1479

Site MY60001

Kuching · Malaysia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1480

Site MD37301

Chisinau · Moldova

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1481

Site NL31010

Amsterdam · Netherlands

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1482

Site NL31009

Den Helder · Netherlands

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1483

Site NL31004

Maastricht · Netherlands

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1484

Site NL31011

Rotterdam · Netherlands

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1485

Site NZ64002

Auckland · New Zealand

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1486

Site NZ64005

Dunedin · New Zealand

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1487

Site NZ64001

Hamilton · New Zealand

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1488

Site NO47001

Stavanger · Norway

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1489

Site PL48002

Gdansk · Poland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1490

Site PL48001

Mysłowice · Poland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1491

Site PL48004

Pozman · Poland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1492

Site PL48005

Słupsk · Poland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1493

Site PL48011

Warsaw · Poland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1494

Site PL48003

Wroclaw · Poland

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1495

Site RO40003

Bucharest · Romania

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1496

Site RO40001

Cluj-Napoca · Romania

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1497

Site RO40004

Cluj-Napoca · Romania

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1498

Site RU70008

Ivanovo · Russia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1499

Site RU70001

Moscow · Russia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1500

Site RU70005

Omsk · Russia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1501

Site RU70009

Saint Petersburg · Russia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1502

Site RU70003

Saint Petersburg · Russia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1503

Site RU70006

Saint Petersburg · Russia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1504

Site RS38102

Belgrade · Serbia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1505

Site RS38101

Belgrade · Serbia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1506

Site SK10223

Bratislava · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1507

Site SK42109

Košice · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1508

Site SK42106

Košice · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1509

Site SK42105

Nitra · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1510

Site SK42103

Prešov · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1511

Site SK42108

Trenčín · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1512

Site SK42107

Žilina · Slovakia

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1513

Site ZA27001

George · South Africa

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1514

Site KR82008

Busan · South Korea

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1515

Site KR82012

Seongnam-si · South Korea

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1516

Site KR82005

Seongnam-si · South Korea

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1517

Site KR82009

Seoul · South Korea

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1518

Site KR82011

Seoul · South Korea

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1519

Site KR82001

Seoul · South Korea

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1520

Site ES34007

Barcelona · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1521

Site ES34003

Barcelona · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1522

Site ES34004

Barcelona · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2WITHDRAWNNCT02960022 ↗
1523

Site ES34011

Girona · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1524

Site ES34012

Madrid · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1525

Site ES34008

Madrid · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1526

Site ES34005

Pamplona · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1527

Site ES34014

Salamanca · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1528

Site ES34010

Santiago de Compostela · Spain

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1529

Site SE46001

Gothenburg · Sweden

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1530

Site SE46003

Umeå · Sweden

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1531

Site TW88607

Guishan · Taiwan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1532

Site TW88601

Kaohsiung City · Taiwan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1533

Site TW88602

Taichung · Taiwan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1534

Site TW88606

Taipei · Taiwan

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1535

Site TH66001

Hat Yai · Changwat Songkhla · Thailand

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1536

Site TH66002

Bangkok · Thailand

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1537

Site TR90002

Beşevler · Ankara · Turkey (Türkiye)

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1538

Site UA38004

Dnipro · Ukraine

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1539

Site UA38005

Kharkiv · Ukraine

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1540

Site UA38001

Kyiv · Ukraine

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1541

Site UA38003

Uzhhorod · Ukraine

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1542

Site GB44009

Bebington · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1543

Site GB44003

Belfast · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1544

Site GB44004

Bristol · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1545

Site GB44014

Cambridge · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1546

Site GB44005

Cardiff · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1547

Site GB44002

Glasgow · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1548

Site GB44006

London · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1549

Site GB44007

Manchester · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1550

Site GB44008

Northwood · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2CompletedNCT02960022 ↗
1551

Site GB44016

Nottingham · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1552

Site GB44001

Sutton · United Kingdom

1 trial
Long-term safety monitoring of enzalutamide in prostate cancer patients continuing previous treatment.
Astellas Pharma Global Development, Inc.Ph 2ActiveNCT02960022 ↗
1553

UCLA Hematology & Oncology ( Site 0003)

Los Angeles · California · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1554

University of California-Irvine Medical Center ( Site 0016)

Orange · California · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1555

UCSF Medical Center at Mission Bay ( Site 0034)

San Francisco · California · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1556

MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)

Washington D.C. · District of Columbia · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1557

University of Michigan ( Site 0021)

Ann Arbor · Michigan · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1558

Memorial Sloan Kettering Cancer Center ( Site 0006)

New York · New York · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1559

UPMC Hillman Cancer Center ( Site 0014)

Pittsburgh · Pennsylvania · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1560

The West Clinic, PLLC dba West Cancer Center ( Site 0005)

Germantown · Tennessee · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1561

Fred Hutchinson Cancer Center ( Site 0013)

Seattle · Washington · United States

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1562

Instituto Alexander Fleming ( Site 0202)

Ciudad Autónoma de Buenos Aires · Buenos Aires · Argentina

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1563

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)

La Rioja · Argentina

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1564

Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)

Macquarie University · New South Wales · Australia

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1565

Liga Norte Riograndense Contra o Câncer ( Site 0271)

Natal · Rio Grande do Norte · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1566

Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)

Porto Alegre · Rio Grande do Sul · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1567

Hospital Moinhos de Vento ( Site 0278)

Porto Alegre · Rio Grande do Sul · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1568

Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)

Bragança Paulista · São Paulo · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1569

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)

Ribeirão Preto · São Paulo · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1570

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)

São José do Rio Preto · São Paulo · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1571

Hospital Alemao Oswaldo Cruz ( Site 0279)

São Paulo · São Paulo · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1572

IPITEC ( Site 0275)

São Paulo · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1573

IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)

São Paulo · Brazil

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1574

BC Cancer - Vancouver Center ( Site 0103)

Vancouver · British Columbia · Canada

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1575

Sunnybrook Research Institute ( Site 0109)

Toronto · Ontario · Canada

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1576

Princess Margaret Cancer Centre ( Site 0102)

Toronto · Ontario · Canada

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1577

CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)

Sherbrooke · Quebec · Canada

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1578

Clinica Universidad Catolica del Maule ( Site 0236)

Talca · Maule Region · Chile

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1579

FALP ( Site 0232)

Santiago · Region M. de Santiago · Chile

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1580

Centro de Oncología de Precisión ( Site 0241)

Santiago · Region M. de Santiago · Chile

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1581

Bradfordhill ( Site 0231)

Santiago · Region M. de Santiago · Chile

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1582

ONCOCENTRO APYS ( Site 0234)

Viña del Mar · Valparaiso · Chile

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1583

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)

Bordeaux · Gironde · France

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1584

Centre Oscar Lambret ( Site 0495)

Lille · Nord · France

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1585

Institut De Cancerologie De L Ouest ( Site 0494)

Saint-Herblain · Pays de la Loire Region · France

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1586

Centre Hospitalier de la Cote Basque ( Site 0496)

Bayonne · Pyrenees-Atlantiques · France

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1587

centre hospitalier lyon sud ( Site 0497)

Pierre-Bénite · Rhone · France

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1588

NCT ( Site 0528)

Heidelberg · Baden-Wurttemberg · Germany

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1589

Universitaetsklinikum Ulm. ( Site 0530)

Ulm · Baden-Wurttemberg · Germany

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1590

Universitaetsklinikum Jena ( Site 0525)

Jena · Thuringia · Germany

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1591

Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)

Hamburg · Germany

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1592

St Vincent's University Hospital ( Site 0463)

Dublin · Dublin · Ireland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1593

Beaumont Hospital, Dublin ( Site 0465)

Dublin · Ireland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1594

Tallaght University Hospital ( Site 0462)

Dublin · Ireland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1595

Rambam Health Care Campus ( Site 0400)

Haifa · Israel

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1596

Hadassah Medical Center ( Site 0404)

Jerusalem · Israel

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1597

Rabin Medical Center ( Site 0402)

Petah Tikva · Israel

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1598

Sheba Medical Center ( Site 0401)

Ramat Gan · Israel

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1599

Sourasky Medical Center ( Site 0403)

Tel Aviv · Israel

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1600

AOU San Luigi Gonzaga di Orbassano ( Site 0434)

Orbassano · Torino · Italy

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1601

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)

Brescia · Italy

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1602

Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)

Milan · Italy

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1603

A.O.U. Federico II di Napoli ( Site 0435)

Naples · Italy

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1604

Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)

Roma · Italy

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1605

Ziekenhuis Gelderse Vallei ( Site 0683)

Ede · Gelderland · Netherlands

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1606

UMC St. Radboud ( Site 0679)

Nijmegen · Gelderland · Netherlands

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1607

Nij Smellinghe ( Site 0684)

Drachten · Provincie Friesland · Netherlands

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1608

Auckland City Hospital ( Site 0831)

Auckland · New Zealand

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1609

Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)

Poznan · Greater Poland Voivodeship · Poland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1610

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)

Warsaw · Masovian Voivodeship · Poland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1611

Uniwersyteckie Centrum Kliniczne ( Site 0588)

Gdansk · Pomeranian Voivodeship · Poland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1612

Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)

Koszalin · West Pomeranian Voivodeship · Poland

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1613

Asan Medical Center ( Site 0925)

Songpagu · Seoul · South Korea

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1614

Severance Hospital Yonsei University Health System ( Site 0924)

Seoul · South Korea

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2ActiveNCT06863272 ↗
1615

Samsung Medical Center ( Site 0926)

Seoul · South Korea

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1616

ICO L Hospitalet ( Site 0617)

L Hospitalet Del Llobregat · Barcelona · Spain

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1617

Hospital Universitario Ramon y Cajal ( Site 0620)

Madrid · Spain

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1618

Hospital Clinico San Carlos ( Site 0618)

Madrid · Spain

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1619

Hospital Universitario 12 de Octubre ( Site 0622)

Madrid · Spain

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1620

Hospital Universitario Virgen del Rocio ( Site 0619)

Seville · Spain

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1621

Taichung Veterans General Hospital ( Site 0902)

Taichung · Taiwan

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1622

Taipei Veterans General Hospital ( Site 0901)

Taipei · Taiwan

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1623

Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)

Adana · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1624

Hacettepe Universitesi Tip Fakultesi ( Site 0648)

Ankara · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1625

Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)

Ankara · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1626

Ankara Bilkent Şehir Hastanesi ( Site 0654)

Ankara · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1627

Koç Üniversitesi Hastanesi ( Site 0656)

Istanbul · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1628

Istanbul Universitesi Cerrahpasa ( Site 0649)

Istanbul · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1629

Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)

Rize · Turkey (Türkiye)

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1630

Addenbrooke's Hospital ( Site 0747)

Cambridge · Cambridgeshire · United Kingdom

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1631

St Bartholomew's Hospital ( Site 0749)

London · London, City of · United Kingdom

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1632

Royal Free Hospital ( Site 0743)

London · London, City of · United Kingdom

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1633

Royal Marsden Hospital (Sutton) ( Site 0741)

London · Surrey · United Kingdom

1 trial
Ifinatamab deruxtecan alone or combined with other drugs for metastatic castration-resistant prostate cancer.
Merck Sharp & Dohme LLCPh 1 / Ph 2RecruitingNCT06863272 ↗
1634

University of Arizona Cancer Center-Orange Grove Campus

Tucson · Arizona · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1635

Banner University Medical Center - Tucson

Tucson · Arizona · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1636

University of Arizona Cancer Center-North Campus

Tucson · Arizona · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1637

Keck Medicine of USC Koreatown

Los Angeles · California · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1638

Emory Johns Creek Hospital

Johns Creek · Georgia · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1639

Loyola Center for Health at Burr Ridge

Burr Ridge · Illinois · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1640

Loyola Medicine Homer Glen

Homer Glen · Illinois · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1641

Rush MD Anderson Cancer Center at Rush Oak Park

Oak Park · Illinois · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1642

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny · Iowa · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1643

University of Iowa Healthcare Cancer Services Quad Cities

Bettendorf · Iowa · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1644

University of Iowa/Holden Comprehensive Cancer Center

Iowa City · Iowa · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1645

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee · Iowa · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1646

Cancer Center of Kansas - Chanute

Chanute · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1647

Cancer Center of Kansas - Dodge City

Dodge City · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1648

Cancer Center of Kansas - El Dorado

El Dorado · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1649

Cancer Center of Kansas-Independence

Independence · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1650

Cancer Center of Kansas-Kingman

Kingman · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1651

Cancer Center of Kansas-Liberal

Liberal · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1652

Cancer Center of Kansas-Manhattan

Manhattan · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1653

Cancer Center of Kansas - McPherson

McPherson · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1654

Cancer Center of Kansas - Newton

Newton · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1655

Cancer Center of Kansas - Parsons

Parsons · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1656

Freeman Physician Group of Pittsburg

Pittsburg · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1657

Cancer Center of Kansas - Pratt

Pratt · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1658

Cancer Center of Kansas - Salina

Salina · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1659

Cancer Center of Kansas - Wellington

Wellington · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1660

Cancer Center of Kansas-Wichita Medical Arts Tower

Wichita · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1661

Ascension Via Christi Hospitals Wichita

Wichita · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1662

Cancer Center of Kansas - Wichita

Wichita · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1663

Cancer Center of Kansas - Winfield

Winfield · Kansas · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1664

Mary Bird Perkins Cancer Center - Metairie

Metairie · Louisiana · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1665

LSU Healthcare Network / Metairie Multi-Specialty Clinic

Metairie · Louisiana · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1666

Mercy Oncology and Hematology - Clayton-Clarkson

Ballwin · Missouri · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1667

Mercy Hospital Washington

Washington · Missouri · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1668

Great Falls Clinic

Great Falls · Montana · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1669

Hope Cancer Care of Nevada

Las Vegas · Nevada · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1670

University Cancer Center

Las Vegas · Nevada · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1671

Memorial Sloan Kettering Basking Ridge

Basking Ridge · New Jersey · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1672

New York-Presbyterian/Brooklyn Methodist Hospital

Brooklyn · New York · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1673

Maimonides Medical Center

Brooklyn · New York · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1674

NYU Langone Hospital - Long Island

Mineola · New York · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1675

Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York · New York · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1676

Memorial Sloan Kettering Nassau

Uniondale · New York · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1677

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati · Ohio · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1678

Central Ohio Breast and Endocrine Surgery

Gahanna · Ohio · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2SUSPENDEDNCT03866382 ↗
1679

OhioHealth Mansfield Hospital

Mansfield · Ohio · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1680

Memorial Hospital

Marysville · Ohio · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1681

University of Cincinnati Cancer Center-West Chester

West Chester · Ohio · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1682

OhioHealth Westerville Medical Campus/Westerville Cancer Center

Westerville · Ohio · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1683

Saint Vincent Hospital

Erie · Pennsylvania · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1684

Jefferson Hospital

Jefferson Hills · Pennsylvania · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1685

UPMC Cancer Center - Monroeville

Monroeville · Pennsylvania · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1686

UPMC-Shadyside Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1687

Wexford Health and Wellness Pavilion

Wexford · Pennsylvania · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1688

University Cancer Specialists - Alcoa

Alcoa · Tennessee · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1689

University of Tennessee - Knoxville

Knoxville · Tennessee · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1690

Mayo Clinic Health System-Eau Claire Clinic

Eau Claire · Wisconsin · United States

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2RecruitingNCT03866382 ↗
1691

Pan American Center for Oncology Trials LLC

San Juan · Puerto Rico

1 trial
Cabozantinib combined with nivolumab and ipilimumab immunotherapies for rare metastatic genitourinary tumors.
National Cancer Institute (NCI)Ph 2ActiveNCT03866382 ↗
1692

Brigham and Women's Hospital

Boston · Massachusetts · United States

1 trial
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
1693

Weisberg Cancer Treatment Center

Farmington Hills · Michigan · United States

1 trial
Olaparib with or without cediranib for advanced metastatic prostate cancer.
National Cancer Institute (NCI)Ph 2NCT02893917 ↗
1694

Clearview Cancer Institute

Huntsville · Alabama · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1695

Sharp HealthCare - Sharp Memorial Hospital

San Diego · California · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1696

H. Lee Moffitt Cancer Center

Tampa · Florida · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1697

Associated Urological Specialists

Chicago Ridge · Illinois · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1698

NorthShore University HealthSystem

Evanston · Illinois · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1699

Ochsner Health - Ochsner Medical Center - New Orleans

New Orleans · Louisiana · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1700

Solaris Health - The Urology Group

Cincinnati · Ohio · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1701

UW Health Carbone Cancer Center

Madison · Wisconsin · United States

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1702

Subei People's Hospital

Yangzhou · Jiangsu · China

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1703

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou · Zhejiang · China

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1704

Huai'an First People's Hospital

Huaian · China

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1705

Renji Hospital Shanghai Jiaotong Univ School of Medicine

Shanghai · China

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1706

Site FR33003

Bordeaux · France

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1707

Site FR33009

Le Mans · France

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1708

Site FR33008

Lille · France

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1709

Site FR33006

Paris · France

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1710

Site FR33004

Strasbourg · France

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1711

Site DE49001

Heinsberg · Germany

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1712

Site IT39004

Milan · Italy

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1713

Site IT39006

Milan · Italy

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1714

Site IT39003

Trento · Italy

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1715

Shizuoka Cancer Center

Sunto-gun · Shizuoka · Japan

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1716

The Cancer Institute Hospital of JFCR

Koto · Tokyo · Japan

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1717

Site PL48007

Gliwice · Poland

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1718

Site PL48005

Mysłowice · Poland

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1719

Site PL48008

Otwock · Poland

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1720

PanOncology Trials

San Juan · Puerto Rico

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1721

Site KR82006

Daegu · South Korea

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1722

Site KR82008

Gwangju · South Korea

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1723

Site ES34006

Barcelona · Catalonia · Spain

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1724

Site ES34005

Barcelona · Spain

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1725

Site ES34008

Barcelona · Spain

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1726

Site ES34003

Santiago de Compostela · Spain

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1727

Site TW88602

Taipei · Taiwan

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1728

Site GB44003

London · United Kingdom

1 trial
ASP5541 hormone therapy drug for prostate cancer patients.
Astellas Pharma Global Development, Inc.Ph 2RecruitingNCT07005154 ↗
1729

University of California at San Diego

La Jolla · California · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1730

Ronald Reagan UCLA Medical Center

Los Angeles · California · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1731

Rocky Mountain Cancer Centers

Aurora · Colorado · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1732

University of Colorado Cancer Center

Aurora · Colorado · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1733

Hartford Hospital

Hartford · Connecticut · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1734

Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital

Washington D.C. · District of Columbia · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1735

Florida Cancer Specialists & Research Institute

Fort Myers · Florida · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1736

University of Iowa Hospital and Clinics

Iowa City · Iowa · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1737

Mission Cancer Blood

Waukee · Iowa · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1738

Johns Hopkins University

Baltimore · Maryland · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1739

University of Michigan Health System

Ann Arbor · Michigan · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1740

Henry Ford Cancer Detroit

Detroit · Michigan · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1741

University Of Minnesota Medical Center

Minneapolis · Minnesota · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1742

XCancer Omaha / Urology Cancer Center

Omaha · Nebraska · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1743

NYU Langone Hospitals

Brooklyn · New York · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1744

NYU Langone Hospital Long Island

Mineola · New York · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1745

NYU Langone Health Laura and Isaac Perlmutter Cancer Center

New York · New York · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1746

Levine Cancer Institute

Charlotte · North Carolina · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1747

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem · North Carolina · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1748

University of Cincinnati

Cincinnati · Ohio · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1749

University Hospital of Cleveland

Cleveland · Ohio · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1750

Compass Oncology

Portland · Oregon · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3CompletedNCT07164443 ↗
1751

VA Portland Health Care System

Portland · Oregon · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1752

Keystone Urology Specialists

Lancaster · Pennsylvania · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1753

Penn Medicine Abramson Cancer Center

Philadelphia · Pennsylvania · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1754

UPMC Cancer Centers

Pittsburgh · Pennsylvania · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1755

Ralph H Johnson Veterans Hospital

Charleston · South Carolina · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1756

Gibbs Cancer Center and Research Institute Pelham

Greer · South Carolina · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1757

Gibbs Cancer Center

Spartanburg · South Carolina · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1758

Tennessee Oncology - Chattanooga

Chattanooga · Tennessee · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1759

Urology Clinics of North Texas

Dallas · Texas · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3CompletedNCT07164443 ↗
1760

Michael E DeBakey VA Medical Center

Houston · Texas · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1761

Texas Oncology West Texas

Wichita Falls · Texas · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1762

Blue Ridge Cancer Care

Roanoke · Virginia · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1763

VA Puget Sound Healthcare System

Seattle · Washington · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1764

Fred Hutchinson Cancer Research Center

Seattle · Washington · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1765

University of Washington

Seattle · Washington · United States

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1766

Warringal Private Hospital

Heidelberg · Australia

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1767

ICON Cancer Care

Kurralta Park · Australia

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1768

AZ Sint-Jan

Bruges · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1769

Cliniques Universitaires Saint Luc

Brussels · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1770

Ghent University Hospital

Ghent · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1771

Az Groeninge

Kortrijk · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1772

Chu Helora Hospital La Louviere Site Jolimont

La Louvière · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1773

CHC MontLegia

Liège · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1774

Clinique Saint Pierre

Ottignies · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1775

ZAS Augustinus

Wilrijk · Belgium

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1776

Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN

Florianópolis · Brazil

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1777

Associacao Hospitalar Moinhos de Vento

Porto Alegre · Brazil

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1778

Arthur J E Child Comprehensive Cancer Centre

Calgary · Alberta · Canada

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1779

BC Cancer Vancouver

Vancouver · British Columbia · Canada

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1780

Lakeridge Health

Oshawa · Ontario · Canada

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1781

CHU de Quebec Universite Laval

Québec · Quebec · Canada

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1782

The First Bethune Hospital of Jilin University

Changchun · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1783

The Third People's Hospital of Chengdu

Chengdu · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1784

West China Hospital of Sichuan University

Chengdu · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1785

Sun Yat Sen University Cancer Center

Guangzhou · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1786

The First Affiliated Hospital of Guangxi Medical University

Nanning · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1787

Nantong Tumor Hospital

Nantong · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1788

The First Affiliated Hospital of Ningbo University

Ningbo · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1789

Zhongnan Hospital Wu Han University

Wuhan · China

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1790

CHRU Brest - Hopital Morvan

Brest · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1791

Centre Oscar Lambret

Lille · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1792

Hopital Saint Joseph

Paris · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1793

CHU Lyon Sud

Pierre-Bénite · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1794

I.C.O. Rene Gauducheau

Saint-Herblain · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1795

Hopitaux universitaires de Strasbourg

Strasbourg · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1796

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy · France

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1797

Staedtisches Klinikum Braunschweig

Braunschweig · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1798

Universitaetsklinikum Duesseldorf

Düsseldorf · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1799

Krankenhaus NorthWest

Frankfurt am Main · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1800

Martini-Klinik am UKE GmbH

Hamburg · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1801

Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen

Heidelberg · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1802

Klinikum rechts der Isar der TU Muenchen

München · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1803

Klinikum Nuernberg Nord

Nuremberg · Germany

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1804

Ospedali Riuniti Foggia

Foggia · Italy

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1805

Azienda Ospedaliera Universitaria Federico II

Naples · Italy

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1806

IOV IRCCS Padova

Padova · Italy

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1807

Azienda Di Rilievo Nazionale E Di Alta Specializzazione

Palermo · Italy

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1808

A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette

Torino · Italy

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1809

Institute of Science Tokyo Hospital

Bunkyō City · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1810

Kyushu University Hospital

Fukuoka · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1811

Saitama Medical University International Medical Center

Hidaka · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1812

Kobe University Hospital

Kobe · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1813

National Hospital Organization Tokyo Medical Center

Meguro Ku · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1814

Yokohama City University Hospital

Yokohama · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1815

Yokosuka Kyosai Hospital

Yokosuka · Japan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1816

Reinier de Graaf Gasthuis

Delft · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1817

Martini Ziekenhuis

Groningen · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1818

Tergooi

Hilversum · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1819

Spaarne Gasthuis

Hoofddorp · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1820

Maastricht UMC

Maastricht · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1821

Canisius-Wilhelmina ZH

Nijmegen · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1822

Isala Kliniek

Zwolle · Netherlands

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1823

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok · Poland

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1824

IN VIVO Sp. z o.o

Bydgoszcz · Poland

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1825

Pan American Center for Oncology Trials LLC

Rio Piedras · Puerto Rico

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1826

Puerto Rico Medical Research Center

San Juan · Puerto Rico

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1827

National Cancer Center

Goyang-si · South Korea

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1828

Chonnam National University Hwasun Hospital

Hwasungun · South Korea

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1829

Chang Gung Memorial Hospital

Kaohsiung City · Taiwan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1830

Linkou Chang Gung Memorial Hospital

Taoyuan · Taiwan

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1831

University Hospitals Birmingham NHS Foundation Trust

Birmingham · United Kingdom

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1832

University College London Hospitals

London · United Kingdom

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1833

The Christie NHS Foundation Trust Christie Hospital

Manchester · United Kingdom

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1834

Royal Marsden Hospital (Sutton)

Sutton · United Kingdom

1 trial
Pasritamig versus placebo with supportive care for late-stage metastatic castration-resistant prostate cancer.
Janssen Research & Development, LLCPh 3RecruitingNCT07164443 ↗
1835

Thomas Hospital

Fairhope · Alabama · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1836

Mobile Infirmary Medical Center

Mobile · Alabama · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1837

University of South Alabama Mitchell Cancer Institute

Mobile · Alabama · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1838

Alaska Regional Hospital

Anchorage · Alaska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1839

Fairbanks Memorial Hospital

Fairbanks · Alaska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1840

CTCA at Western Regional Medical Center

Goodyear · Arizona · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1841

Saint Joseph's Hospital and Medical Center

Phoenix · Arizona · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1842

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Jonesboro · Arkansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1843

University of Arkansas for Medical Sciences

Little Rock · Arkansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1844

Kaiser Permanente-Anaheim

Anaheim · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1845

Kaiser Permanente-Deer Valley Medical Center

Antioch · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1846

Sutter Auburn Faith Hospital

Auburn · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1847

Sutter Cancer Centers Radiation Oncology Services-Auburn

Auburn · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1848

AIS Cancer Center at San Joaquin Community Hospital

Bakersfield · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1849

Kaiser Permanente-Baldwin Park

Baldwin Park · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1850

Kaiser Permanente-Bellflower

Bellflower · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1851

Alta Bates Summit Medical Center-Herrick Campus

Berkeley · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1852

Mills-Peninsula Medical Center

Burlingame · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1853

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Cameron Park · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1854

Eden Hospital Medical Center

Castro Valley · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1855

John Muir Medical Center-Concord

Concord · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1856

City of Hope Corona

Corona · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1857

UC Irvine Health Cancer Center-Newport

Costa Mesa · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1858

Sutter Davis Hospital

Davis · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1859

Kaiser Permanente Dublin

Dublin · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1860

Kaiser Permanente-Fontana

Fontana · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1861

Kaiser Permanente-Fremont

Fremont · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1862

Palo Alto Medical Foundation-Fremont

Fremont · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1863

Fresno Cancer Center

Fresno · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1864

Kaiser Permanente-Fresno

Fresno · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1865

Saint Jude Medical Center

Fullerton · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1866

Marin General Hospital

Greenbrae · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1867

Kaiser Permanente South Bay

Harbor City · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1868

Kaiser Permanente-Irvine

Irvine · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1869

Loma Linda University Medical Center

Loma Linda · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1870

Kaiser Permanente Los Angeles Medical Center

Los Angeles · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1871

Kaiser Permanente West Los Angeles

Los Angeles · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1872

Cedars-Sinai Medical Center

Los Angeles · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1873

Fremont - Rideout Cancer Center

Marysville · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1874

Memorial Medical Center

Modesto · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1875

Kaiser Permanente-Modesto

Modesto · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1876

Community Hospital of Monterey Peninsula

Monterey · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1877

Pacific Cancer Care-Monterey

Monterey · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1878

Palo Alto Medical Foundation-Camino Division

Mountain View · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1879

Palo Alto Medical Foundation-Gynecologic Oncology

Mountain View · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1880

Sutter Cancer Research Consortium

Novato · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1881

Kaiser Permanente Oakland-Broadway

Oakland · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1882

Kaiser Permanente-Oakland

Oakland · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1883

Kaiser Permanente-Ontario

Ontario · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1884

Saint Joseph Hospital - Orange

Orange · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1885

Desert Regional Medical Center

Palm Springs · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1886

Palo Alto Medical Foundation Health Care

Palo Alto · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1887

Stanford Cancer Institute Palo Alto

Palo Alto · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1888

VA Palo Alto Health Care System

Palo Alto · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1889

Kaiser Permanente - Panorama City

Panorama City · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1890

Keck Medical Center of USC Pasadena

Pasadena · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1891

Kaiser Permanente-Rancho Cordova Cancer Center

Rancho Cordova · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1892

Eisenhower Medical Center

Rancho Mirage · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1893

Kaiser Permanente- Marshall Medical Offices

Redwood City · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1894

Kaiser Permanente-Redwood City

Redwood City · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1895

Kaiser Permanente-Richmond

Richmond · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1896

Kaiser Permanente-Riverside

Riverside · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1897

Rohnert Park Cancer Center

Rohnert Park · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1898

Kaiser Permanente-Roseville

Roseville · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1899

Sutter Cancer Centers Radiation Oncology Services-Roseville

Roseville · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1900

Sutter Roseville Medical Center

Roseville · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1901

The Permanente Medical Group-Roseville Radiation Oncology

Roseville · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1902

Kaiser Permanente Downtown Commons

Sacramento · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1903

Mercy Cancer Center - Sacramento

Sacramento · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1904

Sutter Medical Center Sacramento

Sacramento · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1905

Kaiser Permanente-South Sacramento

Sacramento · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1906

South Sacramento Cancer Center

Sacramento · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1907

Kaiser Permanente Sacramento Medical Center

Sacramento · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1908

Kaiser Permanente-San Diego Mission

San Diego · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1909

Kaiser Permanente-San Diego Zion

San Diego · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1910

Rady Children's Hospital - San Diego

San Diego · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1911

Sharp Memorial Hospital

San Diego · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1912

Naval Medical Center -San Diego

San Diego · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1913

California Pacific Medical Center-Pacific Campus

San Francisco · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1914

Kaiser Permanente-San Francisco

San Francisco · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1915

Kaiser Permanente-Santa Teresa-San Jose

San Jose · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1916

Kaiser Permanente San Leandro

San Leandro · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1917

Kaiser Permanente-San Marcos

San Marcos · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1918

Mills Health Center

San Mateo · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1919

Kaiser Permanente-San Rafael

San Rafael · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1920

Kaiser San Rafael-Gallinas

San Rafael · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1921

Kaiser Permanente Medical Center - Santa Clara

Santa Clara · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1922

Palo Alto Medical Foundation-Santa Cruz

Santa Cruz · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1923

Kaiser Permanente-Santa Rosa

Santa Rosa · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1924

Sutter Pacific Medical Foundation

Santa Rosa · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1925

Kaiser Permanente Cancer Treatment Center

South San Francisco · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1926

Kaiser Permanente-South San Francisco

South San Francisco · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1927

Saint Helena Hospital

St. Helena · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1928

Saint Joseph's Medical Center

Stockton · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1929

Kaiser Permanente-Stockton

Stockton · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1930

Palo Alto Medical Foundation-Sunnyvale

Sunnyvale · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1931

Gene Upshaw Memorial Tahoe Forest Cancer Center

Truckee · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1932

City of Hope Upland

Upland · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1933

Kaiser Permanente Medical Center-Vacaville

Vacaville · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1934

Kaiser Permanente-Vallejo

Vallejo · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1935

Sutter Solano Medical Center/Cancer Center

Vallejo · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1936

Kaiser Permanente-Walnut Creek

Walnut Creek · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1937

John Muir Medical Center-Walnut Creek

Walnut Creek · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1938

City of Hope West Covina

West Covina · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1939

Presbyterian Intercommunity Hospital

Whittier · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1940

Woodland Memorial Hospital

Woodland · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1941

Kaiser Permanente-Woodland Hills

Woodland Hills · California · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1942

Rocky Mountain Cancer Centers-Aurora

Aurora · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1943

The Medical Center of Aurora

Aurora · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1944

Boulder Community Foothills Hospital

Boulder · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1945

Rocky Mountain Cancer Centers-Boulder

Boulder · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1946

Rocky Mountain Cancer Centers - Centennial

Centennial · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1947

UCHealth Memorial Hospital Central

Colorado Springs · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1948

Memorial Hospital North

Colorado Springs · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1949

Saint Francis Cancer Center

Colorado Springs · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1950

Cancer Center of Colorado at Sloan's Lake

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1951

Denver Health Medical Center

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1952

Kaiser Permanente-Franklin

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1953

National Jewish Health-Main Campus

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1954

The Women's Imaging Center

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1955

Colorado Blood Cancer Institute

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1956

Presbyterian - Saint Lukes Medical Center - Health One

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1957

Rocky Mountain Cancer Centers-Midtown

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1958

Saint Joseph Hospital - Cancer Centers of Colorado

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1959

Rocky Mountain Cancer Centers-Rose

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1960

Rose Medical Center

Denver · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1961

Mountain Blue Cancer Care Center - Swedish

Englewood · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1962

Rocky Mountain Cancer Centers - Swedish

Englewood · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1963

Swedish Medical Center

Englewood · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1964

Poudre Valley Hospital

Fort Collins · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1965

Mountain Blue Cancer Care Center

Golden · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1966

National Jewish Health-Western Hematology Oncology

Golden · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1967

Saint Mary's Hospital and Regional Medical Center

Grand Junction · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1968

Grand Valley Oncology

Grand Junction · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1969

Banner North Colorado Medical Center

Greeley · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1970

Rocky Mountain Cancer Centers-Greenwood Village

Greenwood Village · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1971

Good Samaritan Hospital - Cancer Centers of Colorado

Lafayette · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1972

Kaiser Permanente-Rock Creek

Lafayette · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1973

Rocky Mountain Cancer Centers-Lakewood

Lakewood · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1974

Rocky Mountain Cancer Centers-Littleton

Littleton · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1975

Kaiser Permanente-Lone Tree

Lone Tree · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1976

Rocky Mountain Cancer Centers-Sky Ridge

Lone Tree · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1977

Sky Ridge Medical Center

Lone Tree · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1978

Banner North Colorado Medical Center - Loveland Campus

Loveland · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1979

Rocky Mountain Cancer Centers-Parker

Parker · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1980

Rocky Mountain Cancer Centers - Pueblo

Pueblo · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1981

National Jewish Health-Northern Hematology Oncology

Thornton · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1982

Rocky Mountain Cancer Centers-Thornton

Thornton · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1983

Intermountain Health Lutheran Hospital

Wheat Ridge · Colorado · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1984

Smilow Cancer Hospital Care Center at Glastonbury

Glastonbury · Connecticut · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1985

Smilow Cancer Hospital Care Center at Greenwich

Greenwich · Connecticut · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1986

Eastern Connecticut Hematology and Oncology Associates

Norwich · Connecticut · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1987

Stamford Hospital/Bennett Cancer Center

Stamford · Connecticut · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1988

Veterans Affairs Connecticut Healthcare System-West Haven Campus

West Haven · Connecticut · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1989

Beebe Medical Center

Lewes · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1990

Beebe South Coastal Health Campus

Millville · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1991

Delaware Clinical and Laboratory Physicians PA

Newark · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1992

Helen F Graham Cancer Center

Newark · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1993

Medical Oncology Hematology Consultants PA

Newark · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1994

Christiana Care Health System-Christiana Hospital

Newark · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1995

Beebe Health Campus

Rehoboth Beach · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1996

TidalHealth Nanticoke / Allen Cancer Center

Seaford · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1997

Christiana Care Health System-Wilmington Hospital

Wilmington · Delaware · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1998

MedStar Washington Hospital Center

Washington D.C. · District of Columbia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
1999

Sibley Memorial Hospital

Washington D.C. · District of Columbia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2000

UM Sylvester Comprehensive Cancer Center at Coral Springs

Coral Springs · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2001

Broward Health North

Deerfield Beach · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2002

Broward Health Medical Center

Fort Lauderdale · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2003

UF Health Cancer Institute - Gainesville

Gainesville · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2004

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2005

UM Sylvester Comprehensive Cancer Center at Hollywood

Hollywood · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2006

The Watson Clinic

Lakeland · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2007

Miami Cancer Institute

Miami · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2008

UM Sylvester Comprehensive Cancer Center at Kendall

Miami · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2009

Health Central

Ocoee · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2010

Memorial Hospital West

Pembroke Pines · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2011

UM Sylvester Comprehensive Cancer Center at Plantation

Plantation · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2012

Saint Joseph's Hospital/Children's Hospital-Tampa

Tampa · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2013

Indian River Medical Center

Vero Beach · Florida · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2014

University Cancer and Blood Center LLC

Athens · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2015

Piedmont Hospital

Atlanta · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2016

Northside Hospital

Atlanta · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2017

Augusta University Medical Center

Augusta · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2018

Northeast Georgia Medical Center Braselton

Braselton · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2019

John B Amos Cancer Center

Columbus · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2020

Northside Hospital-Forsyth

Cumming · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2021

Emory Decatur Hospital

Decatur · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2022

Northside Hospital - Duluth

Duluth · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2023

Northeast Georgia Medical Center-Gainesville

Gainesville · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2024

The Longstreet Clinic - Gainesville

Gainesville · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2025

Northside Hospital - Gwinnett

Lawrenceville · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2026

Atrium Health Navicent

Macon · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2027

Central Georgia Gynecologic Oncology

Macon · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2028

CTCA at Southeastern Regional Medical Center

Newnan · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2029

Harbin Clinic Medical Oncology and Clinical Research

Rome · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2030

Low Country Cancer Care

Savannah · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2031

Memorial Health University Medical Center

Savannah · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2032

Summit Cancer Care-Memorial

Savannah · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2033

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2034

Summit Cancer Care-Candler

Savannah · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2035

Suburban Hematology Oncology Associates - Snellville

Snellville · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2036

Lewis Hall Singletary Oncology Center

Thomasville · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2037

South Georgia Medical Center/Pearlman Cancer Center

Valdosta · Georgia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2038

Hawaii Cancer Care Inc - Waterfront Plaza

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2039

Island Urology

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2040

Queen's Cancer Cenrer - POB I

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2041

Queen's Medical Center

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2042

Straub Clinic and Hospital

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2043

University of Hawaii Cancer Center

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2044

Hawaii Cancer Care Inc-Liliha

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2045

Hawaii Diagnostic Radiology Services LLC

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2046

Kuakini Medical Center

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2047

Queen's Cancer Center - Kuakini

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2048

The Cancer Center of Hawaii-Liliha

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2049

Kaiser Permanente Moanalua Medical Center

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2050

Kapiolani Medical Center for Women and Children

Honolulu · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2051

Straub Medical Center - Kahului Clinic

Kahului · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2052

Castle Medical Center

Kailua · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2053

Wilcox Memorial Hospital and Kauai Medical Clinic

Lihue · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2054

Hawaii Cancer Care - Westridge

‘Aiea · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2055

Pali Momi Medical Center

‘Aiea · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2056

Queen's Cancer Center - Pearlridge

‘Aiea · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2057

Straub Pearlridge Clinic

‘Aiea · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2058

The Cancer Center of Hawaii-Pali Momi

‘Aiea · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2059

The Queen's Medical Center - West Oahu

‘Ewa Beach · Hawaii · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2060

OSF Saint Joseph Medical Center

Bloomington · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2061

Centralia Oncology Clinic

Centralia · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2062

Mount Sinai Hospital Medical Center

Chicago · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2063

John H Stroger Jr Hospital of Cook County

Chicago · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2064

Swedish Covenant Hospital

Chicago · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2065

Advocate Illinois Masonic Medical Center

Chicago · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2066

AMG Crystal Lake - Oncology

Crystal Lake · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2067

Northwestern Medicine Cancer Center Kishwaukee

DeKalb · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2068

Ascension Alexian Brothers - Elk Grove Village

Elk Grove Village · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2069

Elmhurst Memorial Hospital

Elmhurst · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2070

NorthShore University HealthSystem-Evanston Hospital

Evanston · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2071

Saint Francis Hospital

Evanston · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2072

Northwestern Medicine Cancer Center Delnor

Geneva · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2073

NorthShore University HealthSystem-Glenbrook Hospital

Glenview · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2074

Ingalls Memorial Hospital

Harvey · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2075

NorthShore University HealthSystem-Highland Park Hospital

Highland Park · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2076

Duly Health and Care Joliet

Joliet · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2077

Presence Saint Mary's Hospital

Kankakee · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2078

AMG Libertyville - Oncology

Libertyville · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2079

Trinity Medical Center

Moline · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2080

Edward Hospital/Cancer Center

Naperville · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2081

Radiation Oncology of Northern Illinois

Ottawa · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2082

OSF Saint Francis Radiation Oncology at Pekin

Pekin · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2083

OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Peoria · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2084

OSF Saint Francis Medical Center

Peoria · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2085

Edward Hospital/Cancer Center?Plainfield

Plainfield · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2086

Hematology Oncology Associates of Illinois - Skokie

Skokie · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2087

North Shore Medical Center

Skokie · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2088

Central Illinois Hematology Oncology Center

Springfield · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2089

Northwestern Medicine Cancer Center Warrenville

Warrenville · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2090

Midwestern Regional Medical Center

Zion · Illinois · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2091

Michiana Hematology Oncology PC-Crown Point

Crown Point · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2092

Michiana Hematology Oncology PC-Elkhart

Elkhart · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2093

Deaconess Clinic Downtown

Evansville · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2094

Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2095

Sidney and Lois Eskenazi Hospital

Indianapolis · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2096

Community Cancer Center East

Indianapolis · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2097

Community Cancer Center South

Indianapolis · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2098

Community Cancer Center North

Indianapolis · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2099

Springmill Medical Center

Indianapolis · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2100

Community Howard Regional Health

Kokomo · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2101

IU Health Arnett Cancer Care

Lafayette · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2102

Franciscan Saint Anthony Health-Michigan City

Michigan City · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2103

Woodland Cancer Care Center

Michigan City · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2104

Memorial Regional Cancer Center Day Road

Mishawaka · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2105

Michiana Hematology Oncology PC-Mishawaka

Mishawaka · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2106

Baptist Health Floyd

New Albany · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2107

Chancellor Center for Oncology

Newburgh · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2108

Michiana Hematology Oncology PC-Plymouth

Plymouth · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2109

Memorial Hospital of South Bend

South Bend · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2110

Michiana Hematology Oncology PC-Westville

Westville · Indiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2111

Saint Anthony Regional Hospital

Carroll · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2112

Physicians' Clinic of Iowa PC

Cedar Rapids · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2113

Mercy Hospital

Cedar Rapids · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2114

Oncology Associates at Mercy Medical Center

Cedar Rapids · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2115

Heartland Oncology and Hematology LLP

Council Bluffs · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2116

Methodist Jennie Edmundson Hospital

Council Bluffs · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2117

Broadlawns Medical Center

Des Moines · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2118

Iowa Lutheran Hospital

Des Moines · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2119

JCHC McCreery Cancer Center

Fairfield · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2120

UI Healthcare Mission Cancer and Blood - Fort Dodge

Fort Dodge · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2121

Ottumwa Regional Health Center

Ottumwa · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2122

Siouxland Regional Cancer Center

Sioux City · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2123

Methodist West Hospital

West Des Moines · Iowa · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2124

Coffeyville Regional Medical Center

Coffeyville · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2125

Newman Regional Health

Emporia · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2126

Saint Catherine Hospital

Garden City · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2127

Saint Rose Ambulatory and Surgery Center

Great Bend · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2128

University of Kansas Cancer Center-West

Kansas City · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2129

Kansas Institute of Medicine Cancer and Blood Center

Lenexa · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2130

Minimally Invasive Surgery Hospital

Lenexa · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2131

Menorah Medical Center

Overland Park · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2132

Saint Luke's South Hospital

Overland Park · Kansas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2133

Baptist Health Corbin

Corbin · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2134

Oncology Hematology Care Inc-Crestview

Crestview Hills · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2135

Saint Elizabeth Healthcare Edgewood

Edgewood · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2136

Baptist Health Hardin

Elizabethtown · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2137

Saint Elizabeth Healthcare Fort Thomas

Fort Thomas · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2138

Baptist Health Lexington

Lexington · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2139

The James Graham Brown Cancer Center at University of Louisville

Louisville · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2140

Baptist Health Louisville

Louisville · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2141

Baptist Health Madisonville/Merle Mahr Cancer Center

Madisonville · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2142

Baptist Health Paducah

Paducah · Kentucky · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2143

LSU Health Baton Rouge-North Clinic

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2144

Baton Rouge General Medical Center

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2145

Our Lady of the Lake Physician Group

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2146

Our Lady of The Lake

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2147

Mary Bird Perkins Cancer Center

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2148

Ochsner Health Center-Summa

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2149

The NeuroMedical Center-Clinic

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2150

Medical Center of Baton Rouge

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2151

Our Lady of the Lake Medical Oncology

Baton Rouge · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2152

Mary Bird Perkins Cancer Center - Covington

Covington · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2153

Ochsner Hematology Oncology North Shore - Covington (West Region)

Covington · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2154

Women's Cancer Care-Covington

Covington · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2155

Ochsner Medical Center West Bank

Gretna · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2156

Mary Bird Perkins Cancer Center - Houma

Houma · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2157

Oncology Center of The South Incorporated

Houma · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2158

Terrebonne General Medical Center

Houma · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2159

West Jefferson Medical Center

Marrero · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2160

Robert Veith MD LLC

Metairie · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2161

Ochsner LSU Health Monroe Medical Center

Monroe · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2162

University Medical Center New Orleans

New Orleans · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2163

LSU Health Sciences Center at Shreveport

Shreveport · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2164

CHRISTUS Highland Medical Center

Shreveport · Louisiana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2165

Harold Alfond Center for Cancer Care

Augusta · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2166

Eastern Maine Medical Center

Bangor · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2167

MaineHealth Waldo Hospital

Belfast · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2168

MaineHealth Maine Medical Center - Biddeford

Biddeford · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2169

Lafayette Family Cancer Center-EMMC

Brewer · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2170

New England Cancer Specialists - Kennebunk

Kennebunk · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2171

MaineHealth Stephens Hospital

Norway · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2172

Penobscot Bay Medical Center

Rockport · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2173

MaineHealth Cancer Care and IV Therapy - Sanford

Sanford · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2174

MaineHealth Maine Medical Center- Scarborough

Scarborough · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2175

MaineHealth Cancer Care and IV Therapy - South Portland

South Portland · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2176

New England Cancer Specialists - Topsham

Topsham · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2177

New England Cancer Specialists

Westbrook · Maine · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2178

Luminis Health Anne Arundel Medical Center

Annapolis · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2179

Sinai Hospital of Baltimore

Baltimore · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2180

MedStar Union Memorial Hospital

Baltimore · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2181

MedStar Franklin Square Medical Center/Weinberg Cancer Institute

Baltimore · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2182

MedStar Good Samaritan Hospital

Baltimore · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2183

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2184

Walter Reed National Military Medical Center

Bethesda · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2185

UPMC Western Maryland

Cumberland · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2186

University of Maryland Shore Medical Center at Easton

Easton · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2187

Christiana Care - Union Hospital

Elkton · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2188

Frederick Memorial Hospital

Frederick · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2189

MedStar Montgomery Medical Center

Olney · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2190

Northwest Hospital Center

Randallstown · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2191

TidalHealth Peninsula Regional

Salisbury · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2192

Holy Cross Hospital

Silver Spring · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2193

William E Kahlert Regional Cancer Center/Sinai Hospital

Westminster · Maryland · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2194

Beverly Hospital

Beverly · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2195

Tufts Medical Center

Boston · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2196

Boston Medical Center

Boston · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2197

Simonds-Sinon Regional Cancer Center

Fitchburg · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2198

MetroWest Medical Center-Framingham Union Hospital

Framingham · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2199

Addison Gilbert Hospital

Gloucester · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2200

Lowell General Hospital

Lowell · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2201

Baystate Medical Center

Springfield · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2202

UMass Memorial Medical Center - University Campus

Worcester · Massachusetts · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2203

Hickman Cancer Center

Adrian · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2204

C S Mott Children's Hospital

Ann Arbor · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2205

University of Michigan Rogel Cancer Center

Ann Arbor · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2206

Bronson Battle Creek

Battle Creek · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2207

Henry Ford Hematology Oncology - Hayes

Clinton Township · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2208

Corewell Health Dearborn Hospital

Dearborn · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2209

Michigan State University

East Lansing · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2210

OSF Saint Francis Hospital and Medical Group

Escanaba · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2211

Corewell Health Farmington Hills Hospital

Farmington Hills · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2212

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2213

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

Grand Rapids · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2214

Trinity Health Grand Rapids Hospital

Grand Rapids · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2215

William Beaumont Hospital-Grosse Pointe

Grosse Pointe · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2216

Bronson Methodist Hospital

Kalamazoo · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2217

West Michigan Cancer Center

Kalamazoo · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2218

Beacon Kalamazoo

Kalamazoo · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2219

Karmanos Cancer Institute at McLaren Greater Lansing

Lansing · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2220

MyMichigan Medical Center Midland

Midland · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2221

Monroe Cancer Center

Monroe · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2222

Toledo Clinic Cancer Centers-Monroe

Monroe · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2223

Trinity Health Muskegon Hospital

Muskegon · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2224

Corewell Health Lakeland Hospitals - Niles Hospital

Niles · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2225

Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2226

Henry Ford Health Providence Novi Hospital

Novi · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2227

Corewell Health Reed City Hospital

Reed City · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2228

Michigan Cancer Specialists

Roseville · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2229

Oakland Colon Rectal Associates

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2230

Cancer Care Associates PC

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2231

Comprehensive Medical Center PLLC

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2232

Corewell Health Children's

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2233

Corewell Health William Beaumont University Hospital

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2234

Hematology Oncology Consultants PC-Royal Oak

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2235

Oakland Medical Group

Royal Oak · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2236

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2237

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2238

Henry Ford Health Providence Southfield Hospital

Southfield · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2239

Premier Hematology Oncology Care

Sterling Heights · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2240

Mitchell Folbe MD PC

Sterling Heights · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2241

Munson Medical Center

Traverse City · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2242

Michigan Institute of Urology-Town Center

Troy · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2243

Claudia BR Herke MD PC

Troy · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2244

Corewell Health Beaumont Troy Hospital

Troy · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2245

Hematology Oncology Consultants PC-Troy

Troy · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2246

University of Michigan Health - West

Wyoming · Michigan · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2247

Essentia Health - Baxter Clinic

Baxter · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2248

Sanford Joe Lueken Cancer Center

Bemidji · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2249

Essentia Health - Ely Clinic

Ely · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2250

Essentia Health - International Falls Clinic

International Falls · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2251

University of Minnesota/Masonic Cancer Center

Minneapolis · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2252

Essentia Health - Moose Lake Clinic

Moose Lake · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2253

Sanford Cancer Center Worthington

Worthington · Minnesota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2254

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Columbus · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2255

Baptist Cancer Center-Grenada

Grenada · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2256

Hattiesburg Clinic - Hematology/Oncology Clinic

Hattiesburg · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2257

Forrest General Hospital / Cancer Center

Hattiesburg · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2258

Baptist Memorial Hospital and Cancer Center-Union County

New Albany · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2259

Baptist Memorial Hospital and Cancer Center-Oxford

Oxford · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2260

Singing River Hospital

Pascagoula · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2261

Baptist Memorial Hospital and Cancer Center-Desoto

Southhaven · Mississippi · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2262

Saint Luke's Hospital

Chesterfield · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2263

MU Health - University Hospital/Ellis Fischel Cancer Center

Columbia · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2264

Centerpoint Medical Center LLC

Independence · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2265

Saint Luke's Hospital of Kansas City

Kansas City · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2266

The University of Kansas Cancer Center-South

Kansas City · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2267

Research Medical Center

Kansas City · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2268

Saint Luke's East - Lee's Summit

Lee's Summit · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2269

Liberty Hospital

Liberty · Missouri · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2270

Saint Vincent Healthcare

Billings · Montana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2271

Saint Vincent Frontier Cancer Center

Billings · Montana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2272

Saint James Community Hospital and Cancer Treatment Center

Butte · Montana · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2273

Fred and Pamela Buffett Cancer Center - Kearney

Kearney · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2274

Nebraska Hematology and Oncology

Lincoln · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2275

Nebraska Cancer Research Center

Lincoln · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2276

Cancer Partners of Nebraska

Lincoln · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2277

Faith Regional Health Services Carson Cancer Center

Norfolk · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2278

Great Plains Health Callahan Cancer Center

North Platte · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2279

Hematology and Oncology Consultants PC

Omaha · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2280

Nebraska Cancer Specialists - Omaha

Omaha · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2281

Oncology Hematology West PC

Omaha · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2282

Regional West Medical Center Cancer Center

Scottsbluff · Nebraska · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2283

Cancer Therapy and Integrative Medicine

Las Vegas · Nevada · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2284

Center of Hope at Renown Medical Center

Reno · Nevada · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2285

New Hampshire Oncology Hematology PA-Concord

Concord · New Hampshire · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2286

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon · New Hampshire · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2287

Elliot Hospital

Manchester · New Hampshire · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2288

Solinsky Center for Cancer Care

Manchester · New Hampshire · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2289

Dartmouth Cancer Center - Manchester/ DCC Manchester

Manchester · New Hampshire · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2290

Dartmouth Cancer Center - Nashua

Nashua · New Hampshire · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2291

Ocean University Medical Center

Brick · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2292

AtlantiCare Health Park-Cape May Court House

Cape May Court House · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2293

AtlantiCare Surgery Center

Egg Harbor · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2294

Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus

Elizabeth · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2295

Hunterdon Medical Center

Flemington · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2296

Hackensack University Medical Center

Hackensack · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2297

Bayshore Community Hospital

Holmdel · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2298

Monmouth Medical Center Southern Campus

Lakewood · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2299

Cooperman Barnabas Medical Center

Livingston · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2300

Monmouth Medical Center

Long Branch · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2301

Southern Ocean County Medical Center

Manahawkin · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2302

Morristown Medical Center

Morristown · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2303

Inspira Medical Center Mullica Hill

Mullica Hill · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2304

Jersey Shore Medical Center

Neptune City · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2305

Newark Beth Israel Medical Center

Newark · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2306

Capital Health Medical Center-Hopewell

Pennington · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2307

Riverview Medical Center/Booker Cancer Center

Red Bank · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2308

Sidney Kimmel Cancer Center Washington Township

Sewell · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2309

Overlook Hospital

Summit · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2310

Inspira Medical Center Vineland

Vineland · New Jersey · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2311

Lovelace Medical Center-Downtown

Albuquerque · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2312

Southwest Gynecologic Oncology Associates Inc

Albuquerque · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2313

University of New Mexico Cancer Center

Albuquerque · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2314

Presbyterian Kaseman Hospital

Albuquerque · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2315

Memorial Medical Center-Las Cruces

Las Cruces · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2316

Presbyterian Rust Medical Center/Jorgensen Cancer Center

Rio Rancho · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2317

Christus Saint Vincent Regional Cancer Center

Santa Fe · New Mexico · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2318

South Shore University Hospital

Bay Shore · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2319

State University of New York Downstate Medical Center

Brooklyn · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2320

Arnot Ogden Medical Center/Falck Cancer Center

Elmira · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2321

Glens Falls Hospital

Glens Falls · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2322

North Shore University Hospital

Manhasset · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2323

Long Island Jewish Medical Center

New Hyde Park · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2324

Mount Sinai Hospital

New York · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2325

Manhattan Eye Ear and Throat Hospital

New York · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2326

Lenox Hill Hospital

New York · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2327

Rochester General Hospital

Rochester · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2328

Stony Brook University Medical Center

Stony Brook · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2329

SUNY Upstate Medical Center-Community Campus

Syracuse · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2330

Montefiore Medical Center-Einstein Campus

The Bronx · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2331

Montefiore Medical Center-Weiler Hospital

The Bronx · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2332

Children's Hospital at Montefiore

The Bronx · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2333

Montefiore Medical Center - Moses Campus

The Bronx · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2334

Dickstein Cancer Treatment Center

White Plains · New York · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2335

Mission Hospital

Asheville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2336

AdventHealth Infusion Center Asheville

Asheville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2337

Messino Cancer Centers

Asheville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2338

Hope Women's Cancer Centers-Asheville

Asheville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2339

Waverly Hematology Oncology

Cary · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2340

Novant Health Presbyterian Medical Center

Charlotte · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2341

Novant Health Carolina Surgical - Randolph

Charlotte · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2342

Oncology Specialists of Charlotte

Charlotte · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2343

Southern Oncology Specialists-Charlotte

Charlotte · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2344

Southeastern Medical Oncology Center-Clinton

Clinton · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2345

AdventHealth Infusion Center Haywood

Clyde · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2346

Durham VA Medical Center

Durham · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2347

Southeastern Medical Oncology Center-Goldsboro

Goldsboro · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2348

Wayne Memorial Hospital

Goldsboro · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2349

Novant Health Breast Surgery - Greensboro

Greensboro · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2350

AdventHealth Hendersonville

Hendersonville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2351

Novant Health Cancer Institute - Huntersville

Huntersville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2352

Novant Health Presbyterian Medical Center Huntersville

Huntersville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2353

Southern Oncology Specialists-Huntersville

Huntersville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2354

Onslow Memorial Hospital

Jacksonville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2355

Southeastern Medical Oncology Center-Jacksonville

Jacksonville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2356

Novant Health Cancer Institute - Kernersville

Kernersville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2357

Matthews Radiation Oncology Center

Matthews · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2358

Novant Health Cancer Institute - Matthews

Matthews · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2359

Novant Health Cancer Institute - Mooresville

Mooresville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2360

Novant Health Cancer Institute - Mount Airy

Mount Airy · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2361

Novant Health Cancer Institute - Wilkesboro

North Wilkesboro · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2362

FirstHealth of the Carolinas-Moore Regional Hospital

Pinehurst · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2363

Duke Cancer Center Raleigh

Raleigh · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2364

Novant Health Cancer Institute - Rowan

Salisbury · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2365

Rowan Regional Medical Center

Salisbury · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2366

Novant Health Cancer Institute - Statesville

Statesville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2367

Novant Health Cancer Institute - Thomasville

Thomasville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2368

Marion L Shepard Cancer Center - ECU Health Beaufort Hospital

Washington · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2369

AdventHealth Infusion Center Weaverville

Weaverville · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2370

Novant Health Forsyth Medical Center

Winston-Salem · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2371

Winston-Salem Health Care

Winston-Salem · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2372

Wake Forest University Health Sciences

Winston-Salem · North Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2373

Sanford Bismarck Medical Center

Bismarck · North Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2374

Sanford South University Medical Center

Fargo · North Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2375

Sanford Broadway Medical Center

Fargo · North Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2376

Sanford Roger Maris Cancer Center

Fargo · North Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2377

Trinity Cancer Care Center

Minot · North Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2378

Aultman Alliance Community Hospital

Alliance · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2379

UHHS-Chagrin Highlands Medical Center

Beachwood · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2380

Cleveland Clinic Mercy Hospital

Canton · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2381

Aultman Health Foundation

Canton · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2382

Geauga Hospital

Chardon · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2383

Oncology Hematology Care Inc-Eden Park

Cincinnati · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2384

Oncology Hematology Care Inc-Mercy West

Cincinnati · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2385

The Christ Hospital

Cincinnati · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2386

Cincinnati Children's Hospital Medical Center

Cincinnati · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2387

Oncology Hematology Care Inc-Anderson

Cincinnati · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2388

Oncology Hematology Care Inc-Blue Ash

Cincinnati · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2389

Case Western Reserve University

Cleveland · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2390

MetroHealth Medical Center

Cleveland · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2391

Cleveland Clinic Foundation

Cleveland · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2392

Delaware Radiation Oncology

Delaware · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2393

Columbus Oncology and Hematology Associates

Dublin · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2394

Hematology Oncology Center Incorporated

Elyria · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2395

Mercy Cancer Center-Elyria

Elyria · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2396

Oncology Hematology Care Inc-Healthplex

Fairfield · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2397

Toledo Clinic Cancer Centers-Maumee

Maumee · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2398

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center

Maumee · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2399

UH Seidman Cancer Center at Landerbrook Health Center

Mayfield Heights · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2400

UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2401

UH Seidman Cancer Center at Southwest General Hospital

Middleburg Heights · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2402

Dayton Physicians LLC-Signal Point

Middletown · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2403

Saint Charles Hospital

Oregon · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2404

University Hospitals Parma Medical Center

Parma · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2405

UH Seidman Cancer Center at Firelands Regional Medical Center

Sandusky · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2406

Dayton Physicians LLC-Wilson

Sidney · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2407

Trinity's Tony Teramana Cancer Center

Steubenville · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2408

ProMedica Flower Hospital

Sylvania · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2409

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2410

University of Toledo

Toledo · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2411

Toledo Clinic Cancer Centers-Toledo

Toledo · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2412

University Hospitals Sharon Health Center

Wadsworth · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2413

UH Seidman Cancer Center at Saint John Medical Center

Westlake · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2414

UHHS-Westlake Medical Center

Westlake · Ohio · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2415

Integris Southwest Medical Center

Oklahoma City · Oklahoma · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2416

Integris Cancer Institute of Oklahoma

Oklahoma City · Oklahoma · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2417

Cancer Treatment Centers of America

Tulsa · Oklahoma · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2418

Good Samaritan Hospital

Corvallis · Oregon · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2419

Legacy Mount Hood Medical Center

Gresham · Oregon · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2420

Legacy Good Samaritan Hospital and Medical Center

Portland · Oregon · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2421

Kaiser Permanente Northwest

Portland · Oregon · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2422

Legacy Meridian Park Hospital

Tualatin · Oregon · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2423

Jefferson Abington Hospital

Abington · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2424

UPMC Altoona

Altoona · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2425

UPMC-Heritage Valley Health System Beaver

Beaver · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2426

Bryn Mawr Hospital

Bryn Mawr · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2427

UPMC Hillman Cancer Center at Butler Health System

Butler · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2428

UPMC Camp Hill

Camp Hill · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2429

Carlisle Regional Cancer Center

Carlisle · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2430

Christiana Care Health System-Concord Health Center

Chadds Ford · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2431

Chambersburg Hospital

Chambersburg · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2432

Main Line Health Center-Collegeville

Collegeville · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2433

UPMC Hillman Cancer Center - Passavant - Cranberry

Cranberry Township · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2434

Geisinger Medical Center

Danville · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2435

Doylestown Hospital

Doylestown · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2436

Easton Hospital

Easton · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2437

Ephrata Cancer Center

Ephrata · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2438

Ephrata Community Hospital

Ephrata · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2439

UPMC Hamot

Erie · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2440

Main Line Health Center-Exton

Exton · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2441

UPMC Cancer Center at UPMC Horizon

Farrell · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2442

Adams Cancer Center

Gettysburg · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2443

UPMC Hillman Cancer Center in Greenville/UPMC Horizon

Greenville · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2444

WellSpan Medical Oncology and Hematology

Hanover · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2445

UPMC Pinnacle Harrisburg

Harrisburg · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2446

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2447

Geisinger Medical Center-Cancer Center Hazleton

Hazleton · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2448

Penn State Milton S Hershey Medical Center

Hershey · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2449

IRMC Cancer Center

Indiana · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2450

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2451

Armstrong Center for Medicine and Health

Kittanning · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2452

Lancaster General Ann B Barshinger Cancer Institute

Lancaster · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2453

Lancaster General Hospital

Lancaster · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2454

Sechler Family Cancer Center

Lebanon · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2455

Geisinger Medical Oncology-Lewisburg

Lewisburg · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2456

Lewistown Hospital

Lewistown · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2457

UPMC Cancer Center at UPMC McKeesport

McKeesport · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2458

Redeemer Health

Meadowbrook · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2459

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2460

Riddle Memorial Hospital

Media · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2461

UPMC Hillman Cancer Center in Coraopolis

Moon Township · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2462

UPMC Hillman Cancer Center - Part of Frick Hospital

Mount Pleasant · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2463

UPMC Cancer Center-Natrona Heights

Natrona Heights · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2464

UPMC Hillman Cancer Center - New Castle

New Castle · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2465

Suburban Community Hospital and Cancer Center

Norristown · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2466

Paoli Memorial Hospital

Paoli · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2467

Drexel University School of Medicine

Philadelphia · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2468

Thomas Jefferson University Hospital

Philadelphia · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2469

Jefferson Torresdale Hospital

Philadelphia · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2470

Eastern Regional Medical Center

Philadelphia · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2471

Nazareth Hospital

Philadelphia · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2472

Reading Hospital McGlinn Cancer Institute at Phoenixville

Phoenixville · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2473

UPMC-Magee Womens Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2474

Oncology Hematology Association

Pittsburgh · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2475

UPMC-Saint Margaret

Pittsburgh · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2476

UPMC-Mercy Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2477

Geisinger Cancer Services-Pottsville

Pottsville · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2478

Penn State Health Saint Joseph Medical Center

Reading · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2479

Guthrie Medical Group PC-Robert Packer Hospital

Sayre · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2480

Hematology and Oncology Associates of North East Pennsylvania

Scranton · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2481

Community Medical Center

Scranton · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2482

Geisinger Medical Oncology-Selinsgrove

Selinsgrove · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2483

UPMC Cancer Center at UPMC Northwest

Seneca · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2484

Geisinger Medical Group

State College · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2485

Mount Nittany Medical Center

State College · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2486

UPMC Cancer Center-Uniontown

Uniontown · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2487

UPMC Cancer Center-Washington

Washington · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2488

Chester County Hospital

West Chester · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2489

UPMC West Mifflin-Cancer Center Jefferson

West Mifflin · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2490

Reading Hospital

West Reading · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2491

Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2492

UPMC Susquehanna

Williamsport · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2493

Divine Providence Hospital

Williamsport · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2494

Asplundh Cancer Pavilion

Willow Grove · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2495

Lankenau Medical Center

Wynnewood · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2496

Cancer Care Associates of York

York · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2497

WellSpan Health-York Cancer Center

York · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2498

WellSpan Health-York Hospital

York · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2499

UPMC Memorial

York · Pennsylvania · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2500

Newport Hospital

Newport · Rhode Island · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2501

Rhode Island Hospital

Providence · Rhode Island · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2502

Women and Infants Hospital

Providence · Rhode Island · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2503

Miriam Hospital

Providence · Rhode Island · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2504

Smilow Cancer Hospital Care Center - Westerly

Westerly · Rhode Island · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2505

AnMed Health Cancer Center

Anderson · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2506

Beaufort Memorial Hospital

Beaufort · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2507

Prisma Health Cancer Institute - Spartanburg

Boiling Springs · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2508

Roper Hospital

Charleston · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2509

Charleston Oncology - Roper

Charleston · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2510

Lowcountry Hematology Oncology PA-North Charleston

Charleston · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2511

Bon Secours Saint Francis Hospital

Charleston · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2512

Charleston Oncology - Saint Francis

Charleston · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2513

Lowcountry Oncology Associates - West Ashley

Charleston · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2514

Prisma Health Cancer Institute - Easley

Easley · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2515

McLeod Regional Medical Center

Florence · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2516

Gibbs Cancer Center-Gaffney

Gaffney · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2517

Tidelands Georgetown Memorial Hospital

Georgetown · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2518

Greenville Health System Cancer Institute-Andrews

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2519

Saint Francis Hospital

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2520

Prisma Health Cancer Institute - Butternut

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2521

Prisma Health Cancer Institute - Faris

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2522

Prisma Health Greenville Memorial Hospital

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2523

Saint Francis Cancer Center

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2524

Prisma Health Cancer Institute - Eastside

Greenville · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2525

Self Regional Healthcare

Greenwood · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2526

Prisma Health Cancer Institute - Greer

Greer · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2527

Gibbs Cancer Center-Pelham

Greer · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2528

South Carolina Cancer Specialists PC

Hilton Head Island · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2529

The Radiation Oncology Center-Hilton Head/Bluffton

Hilton Head Island · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2530

Lowcountry Oncology Associates - Mount Pleasant

Mt. Pleasant · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2531

Prisma Health Cancer Institute - Seneca

Seneca · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2532

North Grove Medical Park

Spartanburg · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2533

Spartanburg Medical Center

Spartanburg · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2534

Spartanburg Medical Center - Mary Black Campus

Spartanburg · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2535

SMC Center for Hematology Oncology Union

Union · South Carolina · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2536

Avera Cancer Institute-Aberdeen

Aberdeen · South Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2537

Rapid City Regional Hospital

Rapid City · South Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2538

Sanford Cancer Center Oncology Clinic

Sioux Falls · South Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2539

Avera Cancer Institute

Sioux Falls · South Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2540

Sanford USD Medical Center - Sioux Falls

Sioux Falls · South Dakota · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2541

Memorial Hospital

Chattanooga · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2542

Integrity Oncology PLLC-Collierville

Collierville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2543

Cookeville Regional Medical Center

Cookeville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2544

Pulmonary Medicine Center of Chattanooga-Hixson

Hixson · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2545

Tennessee Cancer Specialists-Dowell Springs

Knoxville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2546

Covenant Health Cancer Centers

Knoxville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2547

Covenant Health Cancer Centers - West

Knoxville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2548

Covenant Health Oncology Group - Maryville

Maryville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2549

Baptist Memorial Hospital and Cancer Center-Memphis

Memphis · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2550

Meharry Medical College

Nashville · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2551

Covenant Health Oncology Group - Oak Ridge

Oak Ridge · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2552

Memorial GYN Plus

Ooltewah · Tennessee · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2553

Dell Seton Medical Center at The University of Texas

Austin · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2554

UT MD Anderson - The Woodlands

Conroe · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2555

Parkland Memorial Hospital

Dallas · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2556

Baylor University Medical Center

Dallas · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2557

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2558

Houston Methodist Hospital

Houston · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2559

Memorial Hermann Texas Medical Center

Houston · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2560

UT MD Anderson Cancer Center

Houston · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2561

UT MD Anderson - West Houston

Houston · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2562

Memorial Hermann Northeast Hospital

Humble · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2563

UT MD Anderson - League City

League City · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2564

Covenant Medical Center-Lakeside

Lubbock · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2565

Methodist Children's Hospital of South Texas

San Antonio · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2566

University Hospital

San Antonio · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2567

University of Texas Health Science Center at San Antonio

San Antonio · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2568

UT MD Anderson - Sugar Land

Sugar Land · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2569

Memorial Hermann The Woodlands Hospital

The Woodlands · Texas · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2570

American Fork Hospital / Huntsman Intermountain Cancer Center

American Fork · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2571

Sandra L Maxwell Cancer Center

Cedar City · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2572

Farmington Health Center

Farmington · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2573

Logan Regional Hospital

Logan · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2574

Intermountain Medical Center

Murray · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2575

McKay-Dee Hospital Center

Ogden · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2576

Utah Valley Regional Medical Center

Provo · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2577

Riverton Hospital

Riverton · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2578

University of Utah Sugarhouse Health Center

Salt Lake City · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2579

Utah Cancer Specialists-Salt Lake City

Salt Lake City · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2580

Huntsman Cancer Institute/University of Utah

Salt Lake City · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2581

LDS Hospital

Salt Lake City · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2582

South Jordan Health Center

South Jordan · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2583

Saint George Regional Medical Center

St. George · Utah · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2584

Central Vermont Medical Center/National Life Cancer Treatment

Berlin Corners · Vermont · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2585

University of Vermont Medical Center

Burlington · Vermont · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2586

University of Vermont and State Agricultural College

Burlington · Vermont · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2587

Dartmouth Cancer Center - North

Saint Johnsbury · Vermont · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2588

Danville Regional Medical Center

Danville · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2589

Inova Schar Cancer Institute

Fairfax · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2590

Inova Fair Oaks Hospital

Fairfax · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2591

Inova Fairfax Hospital

Falls Church · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2592

Augusta Health Center for Cancer and Blood Disorders

Fishersville · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2593

Hematology Oncology Associates of Fredericksburg Inc

Fredericksburg · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2594

Centra Alan B Pearson Regional Cancer Center

Lynchburg · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2595

Sovah Health Martinsville

Martinsville · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2596

Bon Secours Memorial Regional Medical Center

Mechanicsville · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2597

Bon Secours Westchester Emergency Center

Midlothian · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2598

Bon Secours Saint Francis Medical Center

Midlothian · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2599

Children's Hospital of The King's Daughters

Norfolk · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2600

Bon Secours Saint Mary's Hospital

Richmond · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2601

Virginia Cancer Institute

Richmond · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2602

Bon Secours Cancer Institute at Reynolds Crossing

Richmond · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2603

VCU Massey Cancer Center at Stony Point

Richmond · Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2604

Cancer Care Center at Island Hospital

Anacortes · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2605

MultiCare Auburn Medical Center

Auburn · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2606

Virginia Mason Bainbridge Island Medical Center

Bainbridge Island · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2607

Virginia Mason Federal Way Medical Center

Federal Way · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2608

Tacoma/Valley Radiation Oncology Centers-Gig Harbor

Gig Harbor · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2609

MultiCare Gig Harbor Medical Park

Gig Harbor · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2610

Northwest Cancer Clinic

Kennewick · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2611

Virginia Mason Lynnwood Medical Center

Lynnwood · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2612

Skagit Regional Health Cancer Care Center

Mount Vernon · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2613

Skagit Valley Hospital

Mount Vernon · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2614

Jefferson Healthcare

Port Townsend · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2615

Peninsula Cancer Center

Poulsbo · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2616

MultiCare Good Samaritan Hospital

Puyallup · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2617

Tacoma/Valley Radiation Oncology Centers-Puyallup

Puyallup · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2618

Minor and James Medical PLLC

Seattle · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2619

Kaiser Permanente Washington

Seattle · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2620

University of Washington Medical Center - Montlake

Seattle · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2621

MultiCare Deaconess Cancer and Blood Specialty Center - Downtown

Spokane · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2622

Providence Sacred Heart Medical Center and Children's Hospital

Spokane · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2623

Spokane Valley Cancer Center-Mayfair

Spokane · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2624

Spokane Valley Cancer Center-Mission

Spokane · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2625

Evergreen Hematology and Oncology PS

Spokane · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2626

MultiCare Deaconess Cancer and Blood Specialty Center - North

Spokane · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2627

MultiCare Deaconess Cancer and Blood Specialty Center - Valley

Spokane Valley · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2628

Tacoma/Valley Radiation Oncology Centers-Jackson Hall

Tacoma · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2629

Mary Bridge Children's Hospital and Health Center

Tacoma · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2630

MultiCare Tacoma General Hospital

Tacoma · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2631

Tacoma/Valley Radiation Oncology Centers-Saint Joe's

Tacoma · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2632

Legacy Cancer Institute Medical Oncology and Day Treatment

Vancouver · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2633

Legacy Salmon Creek Hospital

Vancouver · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2634

Wenatchee Valley Hospital and Clinics

Wenatchee · Washington · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2635

United Hospital Center

Bridgeport · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2636

West Virginia University Charleston Division

Charleston · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2637

Edwards Comprehensive Cancer Center

Huntington · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2638

WVUH-Berkely Medical Center

Martinsburg · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2639

Monongalia Hospital

Morgantown · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2640

West Virginia University Healthcare

Morgantown · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2641

Camden Clark Medical Center

Parkersburg · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2642

Wheeling Hospital/Schiffler Cancer Center

Wheeling · West Virginia · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2643

Aspirus Cancer Care-Antigo-Volm Cancer Center

Antigo · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2644

Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton

Appleton · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2645

Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield

Brookfield · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2646

Ascension Calumet Hospital-Chilton

Chilton · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2647

Marshfield Clinic-Chippewa Center

Chippewa Falls · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2648

HSHS Sacred Heart Hospital

Eau Claire · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2649

Marshfield Clinic Cancer Center at Sacred Heart

Eau Claire · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2650

Aurora Health Center-Fond du Lac

Fond du Lac · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2651

Ascension Southeast Wisconsin Hospital - Franklin

Franklin · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2652

Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson

Franklin · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2653

Saint Vincent Hospital Cancer Center Green Bay

Green Bay · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2654

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2655

Mercyhealth Hospital and Cancer Center - Janesville

Janesville · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2656

Gundersen Lutheran Medical Center

La Crosse · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2657

Marshfield Medical Center - Ladysmith

Ladysmith · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2658

Holy Family Memorial Hospital

Manitowoc · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2659

Marshfield Medical Center

Marshfield · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2660

Aspirus Medford Hospital

Medford · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2661

Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon

Mequon · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2662

Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee

Milwaukee · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2663

Ascension Columbia Saint Mary's Hospital-Milwaukee Campus

Milwaukee · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2664

Ascension Saint Francis Hospital-Milwaukee

Milwaukee · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2665

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2666

Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh

Oshkosh · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2667

Ascension All Saints Hospital-Spring Street-Racine

Racine · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2668

Aspirus Cancer Care-Rhinelander-James Beck Cancer Center

Rhinelander · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2669

Saint Mary's Hospital

Rhinelander · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2670

Lakeview Medical Center-Marshfield Clinic

Rice Lake · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2671

HSHS Saint Nicholas Hospital

Sheboygan · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2672

Aspirus Cancer Care - Stevens Point

Stevens Point · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2673

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2674

Aurora Cancer Care-Waukesha

Waukesha · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2675

Aspirus Cancer Care-Wausau

Wausau · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2676

Marshfield Clinic-Wausau Center

Wausau · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2677

Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa

Wauwatosa · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2678

Aspirus Cancer Care - Wisconsin Rapids

Wisconsin Rapids · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2679

Marshfield Clinic - Wisconsin Rapids Center

Wisconsin Rapids · Wisconsin · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2680

Cheyenne Regional Medical Center-West

Cheyenne · Wyoming · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2681

Big Horn Basin Cancer Center

Cody · Wyoming · United States

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2682

FHP Health Center-Guam

Tamuning · Guam

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2683

Cancer Center-Metro Medical Center Bayamon

Bayamón · Puerto Rico

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2684

Doctors Cancer Center

Manati · Puerto Rico

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2685

San Juan Community Oncology Group

San Juan · Puerto Rico

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2686

San Juan City Hospital

San Juan · Puerto Rico

1 trial
Genetic testing guides targeted drug selection for patients with advanced treatment-resistant solid tumors, lymphomas, or multiple myeloma.
National Cancer Institute (NCI)Ph 2NCT02465060 ↗
2687

University of California Davis

Sacramento · California · United States

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2688

Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center

Boston · Massachusetts · United States

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2689

University of Michigan Health

Ann Arbor · Michigan · United States

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2690

U.T. MD Anderson Cancer Center

Houston · Texas · United States

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2691

Vancouver Prostate Centre

Vancouver · British Columbia · Canada

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2692

London Health Sciences Centre

London · Ontario · Canada

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2693

Ottawa Hospital Research Institute (OHRI)

Ottawa · Ontario · Canada

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2694

University Health Network

Toronto · Ontario · Canada

1 trial
Genomic testing guides neoadjuvant therapy selection for high-risk localized prostate cancer patients.
University of British ColumbiaPh 2RecruitingNCT04812366 ↗
2695

Washington University

St Louis · Missouri · United States

1 trial
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
2696

The Ohio State University

Columbus · Ohio · United States

1 trial
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
2697

Thomas Jefferson University

Philadelphia · Pennsylvania · United States

1 trial
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
2698

Universitaetsklinikum Hamburg Eppendorf

Hamburg · Germany

1 trial
Xaluritamig alone or with GnRH antagonist treats localized prostate cancer before surgery.
AmgenPh 1RecruitingNCT06613100 ↗
2699

CHU de Brest, Boulevard de Tanguy Prigent

Brest · France

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2700

Centre de cancérologie Les Dentellières

Valenciennes · France

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2701

University Hospitals of Derby & Burton NHS Foundation Trust

Derby · Derbyshire · United Kingdom

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2702

The Clatterbridge Cancer Centre NHS Foundation Trust

Liverpool · United Kingdom

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2703

Royal Free London

London · United Kingdom

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2704

Maidstone & Tunbridge Wells NHS Trust

Maidstone · United Kingdom

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2705

Norfolk & Norwich University Hospital NHS Foundation Trust

Norwich · United Kingdom

1 trial
SpaceOAR hydrogel spacers' long-term safety monitored in prostate cancer radiotherapy patients.
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingNCT07300631 ↗
2706

Tennessee Oncology PLLC

Nashville · Tennessee · United States

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2707

START

San Antonio · Texas · United States

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2708

Novartis Investigative Site

Olomouc · Czechia

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2709

Novartis Investigative Site

Odense C · Denmark

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2710

Novartis Investigative Site

Pierre-Bénite · France

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2711

Novartis Investigative Site

Jena · Thuringia · Germany

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2712

Novartis Investigative Site

Essen · Germany

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2713

Novartis Investigative Site

Milan · MI · Italy

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2714

Novartis Investigative Site

Kyoto · Japan

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2715

Novartis Investigative Site

Singapore · Singapore

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2716

Novartis Investigative Site

Barcelona · Spain

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2717

Novartis Investigative Site

Taipei · Taiwan

1 trial
GVV858 alone or with endocrine therapy treats hormone-positive breast cancer and solid tumors.
Novartis PharmaceuticalsPh 1 / Ph 2RecruitingNCT07288359 ↗
2718

Memorial Sloan Kettering Basking Ridge (Consent only and follow up)

Basking Ridge · New Jersey · United States

1 trial
Ultra-hypofractionated radiotherapy targets the prostate and dominant lesion as definitive treatment for intermediate-risk prostate cancer.
Memorial Sloan Kettering Cancer CenterPh 1NCT03269422 ↗
2719

Memorial Sloan Kettering Westchester

East White Plains · New York · United States

1 trial
Ultra-hypofractionated radiotherapy targets the prostate and dominant lesion as definitive treatment for intermediate-risk prostate cancer.
Memorial Sloan Kettering Cancer CenterPh 1NCT03269422 ↗
2720

Memorial Sloan Kettering Nassau (Consent and follow up)

Uniondale · New York · United States

1 trial
Ultra-hypofractionated radiotherapy targets the prostate and dominant lesion as definitive treatment for intermediate-risk prostate cancer.
Memorial Sloan Kettering Cancer CenterPh 1NCT03269422 ↗
2721

Urologic Surgeons of Arizona

Mesa · Arizona · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2722

East Valley Urology Center of Arizona

Queen Creek · Arizona · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2723

Bakersfield Institute of Advanced Urology

Bakersfield · California · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2724

Grimaldi Urology

Chula Vista · California · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2725

Valley Urology

Fresno · California · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2726

Tower Urology,

Los Angeles · California · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2727

Alarcon Urology Center

Montebello · California · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2728

Urology Center of Southern California

Murrieta · California · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2729

Biogenix Molecular

Miami · Florida · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2730

Icahn School of Medicine at Mount Sinai

New York · New York · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2731

Oregon Urology Institut

Springfield · Oregon · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2732

Urology of Virginia

Virginia Beach · Virginia · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2733

Summit Cancer Centers of North Spokane

Spokane · Washington · United States

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2734

CHU de Nantes - Hôtel Dieu

Nantes · France

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2735

Hospital Universitario Vall d'Hebron

Barcelona · Spain

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2736

Hospital Clinic Barcelona

Barcelona · Spain

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2737

Hospital Clinico San Carlos

Madroñera · Spain

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗
2738

Instituto Valenciano de Oncologia

Valencia · Spain

1 trial
Debio 4228 drug undergoes dose-finding study to determine pharmacokinetics and pharmacodynamics in advanced prostate cancer patients.
Debiopharm International SAPh 2NCT06395753 ↗